April 28–29, 2014

9th Childhood Leukemia Symposium

Clarion Congress Hotel Prague, Czech Republic

Final Programme
Rare?
It depends how you look at it

To us, there is no difference between a disease affecting 300 million people and a disease affecting 300 people.

sigma-tau
Rare Disease

Dedicated to providing new therapies and new hope to people with rare diseases

sigma-tau.co.uk
9th Childhood Leukemia Symposium
Monday April 28 to Tuesday April 29, 2014

Clarion Congress Hotel Prague
Freyova 33, 190 00 Prague 9
Czech Republic

CONTENT

WELCOME MESSAGE ................................................................. 2
COMMITTEES ........................................................................ 3
VENUE FLOORPLAN ................................................................. 4
DETAILED SCIENTIFIC PROGRAMME ...................................... 5
LIST OF POSTERS ................................................................. 13
EXHIBITION & SPONSORS ...................................................... 43
SOCIAL EVENTS ................................................................. 46
TRANSPORTATION ................................................................. 48
PRACTICAL INFORMATION A–Z ............................................. 51
MAP ..................................................................................... 54
WELCOME MESSAGE

Dear colleagues,

On behalf of the Czech pediatric hematologists and oncologists I would like to cordially welcome you to Prague at the occasion of the 25th Annual Meeting of the International BFM Study Group (I-BFM SG) held on April 26-27, 2014. It is our pleasure to host such event, this year followed by the 9th Biennial Childhood Leukemia Symposium on April 28-29, 2014. The latter is being held under the auspices of Czech Society of Hematology, 2nd Faculty of Medicine, Charles University, and University Hospital Motol, Prague.

Anticipating your interest in attending both events, we have slightly changed the traditional format of IBFM Meeting and thus the programme itself is more condensed this year. The official programme of the Meeting, preceded by the closed meetings on Friday and Saturday morning, will start at 13:00 on Saturday, April 26, with a lecture given by professor Riehm celebrating 40 years anniversary of West Berlin ALL study. The following sessions on Saturday afternoon and Sunday morning will involve separate and combined committee meetings. The plenary session is scheduled for Sunday afternoon. The programme will conclude with the “ENCCA I-BFM” round table with three distinguished invited speakers: SIOP-Europe President G. Vassal, ENCCA (European Network of Cancer Research in Children and Adolescents) project leader R. Ladenstein and PanCareSurFup initiative leader L. Hjorth will introduce current European activities in pediatric oncology.

Childhood Leukemia Symposium (CLS) will be held through Monday and Tuesday (April 28-29). CLS is organized as a common-type congress with standard structure composed of oral and poster presentations on childhood leukemias and lymphomas. Invited lectures are given by A. Carracedo Pérez from Bilbao, J. Fitzgibbon from London, A. D. Ho from Heidelberg and R. Skinner from Newcastle upon Tyne. The European Working Group on Childhood Myelodysplastic syndrome (EWOG-MDS) actively participates at the CLS by organizing a session on myelodysplastic syndrome and bone marrow failures.

The meeting venue – Clarion Congress Hotel is located in north east part of the city, though we will enjoy the historical heart of Prague as well by means of social events of both meetings. The I-BFM Meeting Dinner will be held in the jewel of Prague Art Nouveau architecture – Municipal House on Saturday, April 26. A pleasant interlude between the two events will be ensured by the classical concert held in the historical building of Charles University on Sunday, April 27. Finally, the CLS Welcome Reception will take place on Monday, April 28 at St. Agnes Convent of the Order of Poor Clares founded in 1231 as the first Gothic building in Prague.

We hope to have fruitful meetings and we look forward to sharing our experiences.

Jan Starý
on behalf of the Local Organising Committee
COMMITTEES

Chairman
Prof. Jan Starý
Department of Pediatric Hematology and Oncology
2nd Faculty of Medicine, Charles University and University Hospital Motol
V Úvalu 84, 150 06 Prague 5, Czech Republic
E-mail: jan.stary@lfmotol.cuni.cz

Scientific Programme Committee

Chairman
Prof. Martin Schrappe
Department of General Pediatrics
University Medical Center Schleswig-Holstein, Campus Kiel
Schwanenweg 20
Tel.: +49 (0) 431 597 1621
D-24105 Kiel, Germany
E-mail: schrappe-ibfm@pediatrics.uni-kiel.de

Members
Momcilo Jankovic (Italy)
Rolf Marschalek (Germany)
Charlotte M. Niemeyer (Germany)
Marry van den Heuvel-Eibrink (Netherlands)
Ajay Vora (United Kingdom)

Local Organizing Committee
Jaroslav Štěrba
Petr Sedláček
Jan Trka
Jan Zuna
Monday, April 28, 2014

08:30 – 10:30, ZENIT+NADIR

**Acute Lymphoblastic Leukemia – Biology I**

**CLS Plenary session**

**01**
Whole-transcriptome sequencing to dissect the biology of early response to treatment in childhood ALL

Grazia Fazio
Centro Ricerca Tettamanti, Università Milano Bicocca

**SPEECH TIME:** 08:30 – 08:45

**02**
Whole exome sequencing reveals an activating STAT5B mutation as common abnormality in pediatric T-ALL

Joachim Kunz
ZKJM Heidelberg, Abt. III, Germany

**SPEECH TIME:** 08:45 – 09:00

**03**
Epithelial membrane protein 1, a novel biomarker in pediatric acute lymphoblastic leukemia

Ingrid M Ariës
Department of Pediatric Oncology/Hematology, Erasmus Medical Center-Sophia Children’s Hospital, Rotterdam, The Netherlands

**SPEECH TIME:** 09:00 – 09:15

**04**
CRLF2 expression and its associated signaling profile in childhood B cell precursor acute lymphoblastic leukemia

Giuseppe Gaipa
M.Tettamanti Research Center, Pediatric Clinic, University of Milan Bicocca, Monza, Italy

**SPEECH TIME:** 09:15 – 09:30

**05**
Super elongation complexes and MLL-rearranged leukemias: hitting the point

Rolf Marschalek
Goethe-University of Frankfurt; Inst. of Pharm. Biology, Germany

**SPEECH TIME:** 09:30 – 09:45

**06**
A rare population of quiescent and drug-resistant cells exists in patients’ ALLs growing in mice

Irmela Jeremias
Helmholtz Center Munich, Germany

**SPEECH TIME:** 09:45 – 10:00

**GUEST LECTURE 1**

The Hunt for Leukemia Stem Cells – is it feasible and does it matter?

Anthony Dick Ho
Department of Medicine V (Hematology, Oncology & Rheumatology) Ruprecht-Karls-University Heidelberg, Germany

**SPEECH TIME:** 10:00 – 10:30

**Chairs:** Martin Schrappe (Germany), Jan Trka (Czech Republic)

Session supported by

AMGEN

Oncology
11:00 – 12:45, ZENIT+NADIR

**Myelodysplastic Syndromes, Myeloproliferative Disorders**

**CLS Plenary session**

**GUEST LECTURE 2**

**Familial AML and MDS: Where are we and where are we headed?**

*Jude Fitzgibbon*

Barts Cancer Institute, Queen Mary, University of London, John Vane Science Centre, London, United Kingdom

**O 07**

**Characteristics of Familial MDS within the EWOG-MDS studies**

*Anne Guderle*

Department of Pediatrics and Adolescent Medicine, Division of Pediatric Hematology and Oncology, University of Freiburg, Freiburg, Germany

**O 08**

**GATA2 deficiency in children and adolescents with MDS**

*Marcin Wlodarski*

Pediatric Hematology and Oncology, University Childrens Hospital Freiburg

**O 09**

**Juvenile myelomonocytic leukemia: Five genes – how many subtypes?**

*Charlotte M. Niemeyer*

Pediatric Hematology and Oncology, University Childrens Hospital Freiburg, Germany

**O 10**

**Reduced intensity conditioning for children with refractory cytopenia of childhood: results of the EWOG-MDS study SCT RC RIC 06**

*Brigitte Strahm*

Medical Center – University of Freiburg Center for Pediatrics Department of Pediatric Hematology and Oncology, Freiburg

**O 11**

**Copy number variations and IKZF1 mutations In pediatric CML**

*Manuela Krumbholz*

Children’s Hospital of the University of Erlangen, Germany

**SPEECH TIME:**

- 11:00 – 11:30
- 11:30 – 11:45
- 11:45 – 12:00
- 12:00 – 12:15
- 12:15 – 12:30
- 12:30 – 12:45

**Chairs:** Charlotte M. Niemeyer (Germany), Marry van den Heuvel-Eirbrink (The Netherlands)
13:00 – 14:00, ZENIT+NADIR

**Amgen Satellite Symposium**

**CLS Satellite symposium**

**Welcome and introduction**
Franco Locatelli, Italy

**Novel agents to address treatment needs in adult patients with ALL**
Cyril Šálek, Czech Republic

**Clinical results with immunotherapy approaches in paediatric patients with ALL**
Arend von Stackelberg, Germany

**Panel discussion and closing remarks**
Panel

**Chair:** Franco Locatelli (Italy)
14:15–16:00, ZENIT+NADIR

Acute Myeloid Leukemia, Hematopoietic Stem Cell Transplantation

CLS Plenary session

O 12
Genetic characterization of pediatric acute megakaryoblastic leukemia
Michael Zwaan
Pediatric Oncology/Hematology, Erasmus MC-Sophia Children’s Hospital, Rotterdam, The Netherlands
SPEECH TIME: 14:15–14:30

O 13
Cytokine-induced killer cells redirected with Chimeric Antigen Receptors against CD33/CD123 antigens efficiently target and eliminate primary Acute Myeloid Leukemia cells in vivo
Sarah Tettamanti
Centro di Ricerca “Matilde Tettamanti”, Department of Pediatrics, University of Milano-Bicocca, Italy
SPEECH TIME: 14:30–14:45

O 14
Cytokine-induced killer (CIK) cells enable elimination of minimal residual disease (MRD) in leukemia patients after allogeneic stem cell transplantation
Eva Rettinger
University Hospital Frankfurt/Main, Department for Children and Adolescents Medicine, Division for Stem Cell Transplantation and Immunology, Goethe-University Frankfurt/Main, Germany
SPEECH TIME: 14:45–15:00

O 15
Recurrent deletions of IKZF1 in pediatric acute myeloid leukemia
Eva Beuling
ErasmusMC-Sophia Children’s Hospital, Rotterdam, The Netherlands
SPEECH TIME: 15:00–15:15

O 16
Childhood Acute Promyelocytic Leukemia: Results of treatment in a single Institution in Argentina
Ana Rossa
Hospital JP Garrahan, Buenos Aires, Argentina
SPEECH TIME: 15:15–15:30

O 17
Genetic aberrations as putative MRD targets in childhood Acute Myeloid Leukaemia
Edwin Sonneveld
Dutch Childhood Oncology Group, The Hague, The Netherlands
SPEECH TIME: 15:30–15:45

O 18
Clofarabin/fludarabin + exposure-targeted busulfan in myeloid and lymphoblastic leukemias in children: first results of a dutch national cohort
Marc Bierings
Utrecht University Children’s Hospital, The Netherlands
SPEECH TIME: 15:45–16:00

Chairs: Gjertan Kaspers (The Netherlands), Petr Sedláček (Czech Republic)
08:30–10:30, ZENIT+NADIR

Acute Lymphoblastic Leukemia – Biology II

CLS Plenary session

O 19
Genomic dissection of the Philadelphia-like expression signature in AIEOP Childhood Acute Lymphoblastic Leukemia

Grazia Fazio
Centro Ricerca Tettamanti, Clinica Pediatrica, Università Milano Bicocca, Osp. San Gerardo/Fondazione MBBM, Monza, Italy

O 20
BCR-ABL1-Like Cases in Pediatric Acute Lymphoblastic Leukemia: a Comparison Between DCOG/Erasmus MC and COG/St. Jude Signatures

Judith M. Boer
Department of Pediatric Oncology/Hematology, Erasmus MC – Sophia Children’s Hospital, Rotterdam, The Netherlands

O 21
IKZF1 Mediates Glucocorticoid Therapy Resistance in B Cell Precursor Acute Lymphoblastic Leukemia

Blanca Scheijen
Radboud University Medical Center, Nijmegen, The Netherlands

O 22
Minor childhood acute lymphoblastic leukemia subclones carrying intragenic IKZF1 deletions at diagnosis rarely contribute to relapse development

Roland Kuipe
Radboud University Medical Center, Nijmegen, The Netherlands

O 23
Constitutional and somatic genomic rearrangements coherently restructure chromosome 21 in acute lymphoblastic leukaemia

Claire Schwab
Northern Institute for Cancer Research, Newcastle upon Tyne, UK

O 24
RAS pathway mutations occur at a high incidence in iAMP21 BCP-ALL; an opportunity for targeted therapy

Sarra L. Ryan
Newcastle University, Northern Institute for Cancer Research, Newcastle upon Tyne, UK

GUEST LECTURE 3
Chasing metabolic alterations in cancer

Arkaitz Carracedo Pérez
University of the Basque Country, Derio, Spain

Chairs: Renate Panzer-Grümayer (Austria), Rolf Marschalek (Germany)
**Clinical Topics**

**CLS Plenary session**

**GUEST LECTURE 4**

*Seeking international consensus in long-term follow-up guidelines for survivors of childhood malignancy*

*Roderick Skinner*

Great North Children’s Hospital, Royal Victoria Infirmary, Department of Paediatric and Adolescent Haematology and Oncology, and Children’s BMT Unit, Newcastle upon Tyne, UK

**SPEECH TIME:** 11:00 – 11:30

---

**O 25**

*Bone Mineral Density After Childhood Cancer, A Study In 410 Very Long Term Adult Survivors*

*Marissa den Hoed*

Erasmus MC – Sophia Childrens Hospital, Rotterdam, The Netherlands

**SPEECH TIME:** 11:30 – 11:45

---

**O 26**

*Clofarabine in combination with PEG-asparaginase in the frontline treatment of childhood acute lymphoblastic leukemia: A feasibility report from the CoALL 08-09 trial*

*Gabriele Escherich*

University hospital Hamburg Eppendorf, Germany

**SPEECH TIME:** 11:45 – 12:00

---

**O 27**

*TLR4 Asp299Gly variant confers strong protection against BK virus-associated hemorrhagic cystitis after hematopoietic stem cell transplantation in children*

*Bernd Gruhn*

Jena University Hospital, Jena, Germany

**SPEECH TIME:** 12:00 – 12:15

---

**O 28**

*Severe hypertriglyceridemia during therapy for childhood acute lymphoblastic leukemia*

*Deepa Bhojwani*

St Jude Children’s Research Hospital, Memphis TN, USA

**SPEECH TIME:** 12:15 – 12:30

---

**O 29**

*Toxicity of very prolonged PEGasparaginase and Erwinia asparaginase courses in relation to asparaginase activity levels*

*Wing Tong*

Erasmus MC – Sophia Children’s Hospital, Rotterdam, The Netherlands

**SPEECH TIME:** 12:30 – 12:45

---

**O 30**

*Clinical significance of NPM-ALK expression in bone marrow and peripheral blood and the plasma anti-ALK antibody level at diagnosis in ALK-positive anaplastic large cell lymphoma*

*Yuka Yamashita*

Nagoya Medical Center, Japan

**SPEECH TIME:** 12:45 – 13:00

---

**Chairs:** Jan Starý (Czech Republic), Momcilo Jankovic (Italy)
13:00 – 13:00 Farewel, ZENIT+NADIR
Best poster Awards ceremony

Chair: Jan Starý (Czech Republic)
List of posters

Poster session – Monday, April 28, 2014; 16:00–18:30

P 01
The clinical value of microRNAs in pediatric ALL
Farhad Akbari Moqadam, Ellen Lange-Turenhout, Diana Schotte, Judith Boer, Ingrid Ariës, João Marchante, Arian van der Veer, Rob Pieters, Monique den Boer
Sophia Children’s Hospital – Erasmus MC, Rotterdam, Netherlands

P 02
The contribution of CD49F to the flowcytometric minimal residual disease determination in pediatric B cell acute lymphoblastic leukemia
Canan Albayrak, Davut Albayrak
Medical Faculty of Ondokuz Mayis University, Samsun, Turkey

P 03
IKZF1 genetic susceptibility and IKZF1 somatic aberrations in B cell precursor acute lymphoblastic leukemia
Mariana Emerenciano, Thayana C Barbosa, Priscilla M S Ferreira, Maria S Pombo-de-Oliveira
Pediatric Hematology-Oncology Program, INCA, Rio de Janeiro, Brazil

P 04
Expression profiling of adult acute lymphoblastic leukemia identifies a BCR-ABL1-like subgroup characterized by high relapse rate and non-response to treatment
Judith M. Boer¹, Bronno van der Holt², Carla Exalto², Mathijs A. Sanders³, Jan J. Cornelissen³, Rob Pieters¹, Peter J.M. Valk², Monique L. den Boer³, Anita W. Rijneveld³
1 Department of Pediatric Oncology/Hematology, Erasmus MC – Sophia Children’s Hospital, Rotterdam, The Netherlands
2 HOVON Data Center, Erasmus MC Cancer Institute, Clinical Trial Center, Rotterdam, Netherlands
3 Department of Hematology, Erasmus MC, Rotterdam, The Netherlands

P 05
Comparison between Western Blot and Flow Cytometry in the detection of PTEN and mTOR in Pediatric T-Cell Acute Lymphoblastic Leukemia
Giuseppe Gaipa¹, Paola Bonaccorso², Cristina Bugarin¹, Grazia Fazio¹, Luca Lo Nigro², Giovanni Cazzaniga¹, Andrea Biondi¹, Giuseppe Gaipa¹
1 M. Tettamanti Research Center, Pediatric Clinic, University of Milan Bicocca, Monza, Italy
2 Center of Pediatric Hematology Oncology, Azienda Policlinico – OVE

P 06
Study on the mechanism of homodimerization of the mutant IL7Rα
Livia Campos, Gisele Olinto Libanio Rodrigues, Priscila Pini Zenatti, Jose Andres Yunes
Centro Infantil Boldrini, Sao Paulo, Brazil

P 07
Glycolysis and in vitro ALL resistance to asparaginase
Rafael Canevarolo¹, Carolina Melo¹, Silvia Brandalise¹, Ana Zeri², José Yunes¹
1 Centro Infantil Boldrini, Sao Paulo, Brazil
2 Laboratorio Nacional de Biosciências, Brazil
**P 08**

**PAX5 fusion genes lead to the Src kinase LCK over-expression and activate STAT5 signaling pathway**

Valeria Cazzaniga¹, Cristina Bugarin¹, Marco Giordan², Chiara Palmi¹, Angela Maria Savino¹, Geertruy te Kronnie³, Giuseppe Gaipa¹, Andrea Biondi¹, Grazia Fazio¹, Giovanni Cazzaniga¹

¹ Centro Ricerca M. Tettamanti, Monza, Italy
² Department of Women’s and Children’s Health, University of Padova, Italy

**P 09**

**Concurrent deletions of IKZF1 and PAX5, CDKN2A, CDKN2B or PAR1 (IKZF1plus) confer a very poor prognosis in pediatric acute lymphoblastic leukemia**

Elif Dagdan¹, Marketa Zaliova², Petra Dörge¹, Anja Mörckel¹, Martin Zimmermann¹, Andrea Teigler-Schlegel⁴, Rolf Koehler³, Claus R. Bartram⁵, Julia Alten⁶, Denis Schewe³, Christian Kratz¹, Richard S. Houlston⁶, Martin Schrappe⁶, Gunnar Cario³, Martin Stanulla¹

¹ Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany
² Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany; CLIP – Childhood Leukemia Investigation Prague, Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
³ Department of Pediatrics, University Hospital Schleswig – Holstein, Kiel, Germany
⁴ Oncogenetic laboratory, Pediatric Hematology and Oncology, University of Giessen, Giessen, Germany
⁵ Department of Human Genetics, University of Heidelberg, Heidelberg, Germany
⁶ Institut of Cancer Research, Division of Genetics and Epidemiology, Sutton, United Kingdom

**P 10**

**Sequential analysis of RAS mutations in infant MLL-rearranged acute lymphoblastic leukemia**

Mariana Emerenciano, Thayana C Barbosa, Bruno A Lopes, Maria S Pombo-de-Oliveira

Pediatric Hematology-Oncology Program – INCA, Rio de Janeiro, Brazil

**P 11**

**Chromothripsis as an indicator of underlying TP53 mutation and Li-Fraumeni-syndrome in aneuploid childhood leukemia**

Ute Fischer¹, Cai Chen², Christoph Bartenhagen³, Michael Gombert¹, Vera Binder¹, Vera Okpanyi¹, Andrea Teigler-Schlegel⁴, Jutta Bradtke⁴, Silja Roettgers⁴, Jochen Harbott⁴, Sebastian Ginzel¹

¹ Department of Pediatric Oncology, Hematology and Clinical Immunology, University Children’s Hospital, Medical Faculty, Heinrich Heine University, Duesseldorf, Germany
² Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, China
³ Institute of Medical Informatics, University of Muenster, Muenster, Germany
⁴ Department of Pediatric Hematology and Oncology, University Giessen, Giessen, Germany

**P 12**

**Pharmacogenetics of Micrornas and Micrornas Biogenesis Machinery in Pediatric Acute Lymphoblastic Leukemia**

Africa Garcia-Orad¹, Elixabet Lopez-Lopez¹, Angela Gutierrez-Camino², M Angeles Piñan³, Jose Sanchez-Toledo⁴, Javier Uriz⁵, Javier Ballesteros⁶, Purificación García-Miguel⁷, Aurora Navajas⁸

¹ Department of Genetics, Physical Anthropology and Animal Physiology, University of the Basque Country (UPV/EHU), Leioa, Spain
² Department of Genetics, Physical Anthropology and Animal Physiology, University of the Basque Country (UPV/EHU), Spain
³ Service of Hematology and Hemotherapy, University Hospital Cruces, Spain
⁴ Service of Pediatric Oncology and Hematology, University Hospital Vall d’Hebron, VHIR, Spain
⁵ Unit of Pediatric Oncohematology, University Hospital Donostia, Spain
⁶ Department of Neurosciences, University of the Basque Country (UPV/EHU), Spain
⁷ Service of Pediatric Oncohematology, University Hospital La Paz, Spain
⁸ Unit of Pediatric Hematology/Oncology, University Hospital Cruces, Spain
P 13
Non-coding RNAs-related polymorphisms in pediatric acute lymphoblastic leukemia susceptibility

Africa Garcia-Orad1, Angela Gutierrez-Camino1, Elixabet Lopez-Lopez1, Idoia Martin-Guerrero1, M Angeles Piñan2, Purificacion Garcia-Miguel3, Jose Sanchez-Toledo4, Ana Carbone Bañeres5, Javier Uriz6, Aurora Navajas7

1 Department of Genetics, Physical Anthropology and Animal Physiology, University of the Basque Country (UPV/EHU), Leioa, Spain,
2 Department of Hematology and Hemotherapy, University Hospital Cruces, Spain
3 Service of Pediatric Oncohematology, University Hospital La Paz, Spain
4 Service of Pediatric Oncology and Hematology, University Hospital Vall d’Hebron, VHIR, Spain
5 Unit of Pediatric Oncohematology, University Hospital Miguel Servet, Spain
6 Unit of Pediatric Oncohematology, University Hospital Donostia, Spain
7 Unit of Pediatric Hematology/Oncology, University Hospital Cruces, Spain

P 14
The Histone Deacetylase Inhibitor Panobinostat (LBH-589) Impinges on MLL-rearranged ALL in a Xenograft Mouse Model

Patricia Garrido Castro, Eddy HJ van Roon, Sandra S Mimoso Pinhancos, Pauline Schneider, Mark JB Kerstjens, Rob Pieters, Ronald W Stam

Dept. of Pediatric Oncology/Hematology, Erasmus MC – Sophia Children’s Hospital, Rotterdam, The Netherlands

P 15
Interleukin-15 enhances cellular proliferation via ERK1/2 and up-regulates CNS homing molecules in pre-B acute lymphoblastic leukaemia

Mark Williams1, Yasar Yousafzai1, Ruaidhrí Carmody1, Shuji Sai2, Karen Chapman2, Allison Blair3, Brenda Gibson4, Gerard Graham1, Angela Thomas3, Charlotte Cox3, Christina Halsey1

1 University of Glasgow, UK,
2 University of Edinburgh, UK
3 University of Bristol, UK
4 Royal Hospital for Sick Children, Yorkhill, Glasgow, UK
5 Royal Hospital for Sick Children, Edinburgh, UK

P 16
Childhood pre-B acute lymphoblastic leukaemia cells capable of central nervous system engraftment are common, heterogeneous and transit the blood-cerebrospinal fluid barrier

Yasar Yousafzai1, Mark Williams1, Klaus Rehe2, Simon Bomken2, Paul Sinclair2, Victoria Weston3, Lisa Russell2, Olaf Heidenreich2, Julie Irving2, Josef Vormoor2, Brenda Gibson4, Gerard Graham3, Christina Halsey2

1 University of Glasgow, UK
2 Northern Institute for Cancer Research, Newcastle University, Newcastle, UK
3 School of Cancer Sciences, University of Birmingham, UK
4 Department of Paediatric Haematology, Royal Hospital for Sick Children, Yorkhill, Glasgow, UK
5 Centre for Immunobiology, Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, UK
L-asparaginase causes metabolic reprogramming in ALL cells
Ivana Hermanova1, Karel Valis2, Hana Nuskova3, Karel Fiser4, Sonia Fernández5, Amaia Arruabarrena Aristorena4, Josef Houštěk4, Arkaitz Carracedo5, Jan Trka1, Julia Starkova1
1 CLIP – Molecular Genetics, Dept. Paediatric Haematology/Oncology, 2nd Faculty of Medicine, Charles University Prague, Czech Republic
2 Laboratory of Molecular Structure Characterization Institute of Microbiology, Academy of Sciences of the Czech Republic
3 Department of Bioenergetics, Institute of Physiology, Academy of Sciences of the Czech Republic
4 CLIP, Dept. Paediatric Haematology/Oncology, 2nd Faculty of Medicine, Charles University Prague, Czech Republic
5 CIC bioGUNE Technology Park of Bizkaia, Spain
6 CIC bioGUNE Technology Park of Bizkaia, Spain; Ikerbasque, Bilbao, Spain

Use of BCR/ABL genomic breakpoint for MRD monitoring in ALL and its comparison with other standard methods
Lenka Hovorkova1, Marketa Zaliova1, Katerina Muzikova1, Eva Fronkova1, Jan Stary2, Jan Trka1, Jan Zuna1
1 CLIP – Childhood Leukemia Investigation Prague, Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
2 Pediatric Hematology/Oncology, Charles University and University Hospital Motol, Prague, Czech Republic

Genomic Heterogeneity in Pediatric Acute Lymphoblastic Leukemia
Marta Jeison1, Sarah Elitzur2, Michal Hameiri-Grossman3, Nir A. Sharon4, Jacques Mardoukh4, Gil Gilad2, Gali Avrahami2, Batia Stark2, Isaac Yaniv5, Smadar Avigad3
1 Schneider Children’s Medical Center of Israel
2 Sackler Faculty of Medicine, Tel Aviv University, Pediatric Hematology Oncology, Schneider Children’s Medical Center of Israel, Petah Tikva, Israel.
3 Molecular Oncology, Felsenstein Medical Research Center,Schneider Children’s Medical Center of Israel, Petah Tikva, Israel.
4 Cancer Cytogenetic and Molecular Cytogenetic Laboratory, Schneider Children’s Medical Center of Israel, Petah Tikva, Israel.
5 Molecular Oncology, Felsenstein Medical Research Center, Petah Tikva, Israel, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Pediatric Hematology Oncology,Schneider Children’s Medical Center of Israel, Petah Tikva, Israel

Qualitative PCR for MRD detection up to 10-3 levels
Patricia Yoshioka Jotta1, Mônica Aparecida Ganazza1, Amanda Bortolini Silveira1, André Bortolini Silveira1, Marcos Viana Borato2, Rosemary Otobo1, Eduardo Matsuda1, Vitoria Regia Pinheiro1, Silvia Regina Brandalise1, Jose Andres Yunes1
1 Centro Infantil Boldrini, Sao Paulo, Brazil,
2 Universidade Federal de Minas Gerais, Brazil

Flow Cytometry-based Method of Affinity Proteomics Reveals Expression, Post-translational Modification and Proteolysis in Primary Childhood Acute Leukemias
Veronika Kanderova1, Daniela Kuzilkova1, Jan Stuchly1, Weiwei Wu2, Anders Holm2, Heidi Slåstad2, Karel Fiser1, Ondrej Hrusak1, Fridtjof Lund-Johansen2, Tomas Kalina1
1 CLIP, Dpt Pediatric Hematology/Oncology, 2nd Faculty of Medicine, Prague, Czech Republic
2 Dpt. Immunology, Rikshospitalet, University of Oslo, Norway
P 22
Expression of CD133-2 on B-ALL cells as a prospective marker, predicting MRD level at day 15 in children with leukemia
Mamuka Khvedelidze, Asmat Shengelaia, Tamar Javakhadze
M. Tashvili Children’s Central Hospital, Tbilisi, Georgia

P 23
Post-induction minimal residual disease (MRD) detection in childhood acute lymphoblastic leukemia (ALL) BFM trial using immunoglobulin gene rearrangement next generation profiling
Michaela Kotrová, Kateřina Mužíková, Ester Mejstříková, Violeta Bakardjieva-Mihaylova, Karel Fišer, Jan Stuchlí, Jan Trka, Eva Froňková
CLIP Laboratory Centre, Department of Paediatric Haematology and Oncology, Charles University, 2nd School of Medicine and University Hospital Motol, Prague, Czech Republic

P 24
CD22 expression and its function in B cell precursor blasts. Implication for flow cytometric evaluation and immunotherapy
Daniela Kuzilkova1, Veronika Kanderova1, Leonid Karawojew2, Tomas Kalina1, Ondrej Hrusak1, Ester Mejstrikova1
1 Childhood Leukaemia Investigation Prague (CLIP) – Cytometry, Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Prague, Czech Republic
2 Department of Oncology and Hematology CVK/CBB, Charité – Universitätsmedizin Berlin, Germany

P 25
Identification and functional characterization of leukemia initiating cells in acute lymphoblastic leukemia
Luca Trentin, Manon Queudeville, Sarah M. Eckhoff, Nabiul Hasan, Klaus-Michael Debatin, Lueder H. Meyer
Ulm University, Germany

P 26
In vivo response to remission induction poly-chemotherapy in NOD/SCID/huALL reflects patient risk and outcome
Vera Münch, Hasan Nabiul, Melanie Schirmer, Sarah Mirjam Eckhoff, Klaus-Michael Debatin, Lüder Hinrich Meyer
Department of Pediatrics and Adolescent Medicine, Ulm University, Germany

P 27
Ratios of Immunoproteasome over Constitutive Proteasome Expression are an Indicator for Sensitivity to Bortezomib-containing Reinduction Chemotherapy in Pediatric Relapsed AML and ALL
Denise Niewerth1, Geritjan Kaspers1, Gerrit Jansen2, Johan van Meerloo2, Sonja Zweegman3, Gaye Jenkins4, James Whitlock2, Stephen Hunger4, Xiaomin Lu5, Jacqueline Cloos1, Terzah Horton4
1 Department of Pediatric Oncology/Hematology, VU University Medical Center, Amsterdam, The Netherlands
2 Department of Pediatric Rheumatology, VU University Medical Center, Amsterdam, The Netherlands
3 Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands
4 Texas Children’s Cancer and Hematology Centers, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA
5 Department of Pediatrics, Hospital for Sick Kids, Toronto, Canada
6 Department of Pediatrics, University of Colorado Health Sciences Center, USA
7 COG Operations Office, Arcadia CA, USA
Interleukin-7 receptor (IL17R) gene mutation and CD127 cellular expression in T-cell acute lymphoid leukemia

Maria S. Pombo de Oliveira¹, Elda Pereira Noronha¹, Gisele Olinto Libanio Rodrigues², Carolina Paz Zampier¹, Camilla F C G Andrade¹, Leandro S Thiago³, Eugenia G T Pina¹, José André Yunes⁴
¹ Pediatric Hematology - Oncology Program, Instituto Nacional do Cancer, Rio de Janeiro, Brazil
² Centro Infantil Boldrini, Campinas, São Paulo, Brazil

Genetically modified cytokine-induced killer (CIK) cells for targeted cancer therapy

Sarah Oelsner¹, Eva Rettinger², Verena Pfirrmann², Miriam E. Friede³, Winfried S. Wels², Peter Bader²
¹ Goethe University, Frankfurt, Germany
² Goethe University Frankfurt, Hospital for Children and Adolescents, Dept. Stem Cell Transplantation and Immunology, Frankfurt am Main, Germany
³ Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt am Main, Germany

KIRs gene profile in pediatric B acute lymphoblastic leukemia (ALL)

Zoe Dorothea Pana¹, Rigini Papi², Emmanuel Hatzipantelis¹, Athanassios Tragianidis¹, Evangelia Farmaki³, Dimitrios Kyriakidisº, Theodotis Papageorgiou¹, Fani Athanassiadou¹
¹ Pediatric Hematology Oncology Unit, 2nd Pediatric Department, AHEPA General Hospital, Thessaloniki, Greece
² Department of Medicine, University of Trotters, Frankfurt am Main, Germany
³ Pediatric Department, Hippokration General Hospital, Aristotle University, Thessaloniki, Greece

Monoclonal antibody production against the mutant IL7Rα homodímero

Priscila Pini Zenatti¹, Ana Carolina Arruda¹, Angelo Laranjeira², Livia Campos¹, Gisele Olinto¹, Jörg Köbarg³, José André Yunes¹
¹ Centro Infantil Boldrini, Sao Paulo, Brazil
² Unicamp, Campinas, Brazil
³ Laboratório Nacional de Biociências

Autophagy is regulated by the TEL-AML1 fusion protein via Vps34 and is important for leukemic survival and drug resistance

Roel Polak, Cindy van der Leije, Rosanna van den Dungen, Rob Pieters, Miranda Buitenhuis, Monique den Boer Erasmus MC, Rotterdam, The Netherlands

BMP-4 levels and pathway status in childhood B-ALL of low-/intermediate-risk groups identify children with poor outcome

Manuel Ramirez¹, Ana Entrena², Carolina Martínez-Laperche¹, Lidia Fernández-Sevilla², Gustavo Melen¹, Álvaro Lassaletta¹, Luis Madero¹, Alberto Varas², Angeles Vicente²
¹ Hospital Universitario Niño Jesús, Madrid, Spain
² Department of Cell Biology, School of Medicine, Complutense University, Madrid, Spain

Identification of genetics alterations associated with mutant IL7Rα in ALL-T

Gisele Rodrigues¹, Elda Noronha², Livia Campos¹, Priscila Zenatti¹, André Silveira¹, Patricía Jotta¹, Maria Pombo-de-Oliveira², Silvia Brandalise¹, Francisco Lobo³, José Yunes¹
¹ Centro Infantil Boldrini, Sao Paulo, Brazil
² Instituto Nacional do Câncer, Rio de Janeiro, Brazil
³ Laboratório Multiusuário de Bioinformática EMBRAPA Informática Agropecuária, Sao Paulo, Brazil
P 35

Role of the histone deacetylase

Angela Maria Savino1, Chiara Palmi1, Grazia Fazio1, Michela Bardini1, Francesca Rizzo1, Valeria Cazzaniga1, Cristina Bugarin1, Gianluca Fossati2, Andrea Biondi1, Giovanni Cazzaniga1

1 Pediatric Department, Tettamanti Research Center, University of Milano – Bicocca, San Gerardo Hospital, Monza, Italy
2 Italfarmaco S.p.a. Via dei Lavoratori, 54 20092 Cinisello Balsamo (MI), Italy

P 36

Genome-wide analysis of T cell acute lymphoblastic leukemia with subsequent development of Langerhans cell histiocytosis

Masafumi Seki1, Motohiro Kato1, Ryo Oyama2, Kenichi Yoshida2, Yusuke Sato2, Yuichi Shiraishi2, Kenichi Chiba2, Hiroko Tanaka2, Yuki Arakawa2, Hiroshi Kishimoto2, Satoru Miyano2, Akira Oka1, Ryoji Hanada2, Seishi Ogawa2, Katsuyoshi Koh2, Junko Takita1

1 Department of Pediatrics, The University of Tokyo, Japan
2 Department of Hematology/Oncology, Saitama Children’s Medical Center, Japan
3 Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Japan
4 Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Japan
5 Department of Pathology, Saitama Children's Medical Center, Japan
6 Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Japan

P 37

Smac mimetics overcome apoptosis resistance in high risk acute lymphoblastic leukemia in a preclinical ALL xenograft model

Melanie Schirmer, Manon Queudeville, Luca Trentin, Sarah Mirjam Eckhoff, Lüder Hinrich Meyer, Klaus-Michael Debatin

University Medical Center Ulm, Germany

P 38

Leukemic pattern of HOX gene expression is driven by genetic aberrations through epigenetic modifiers

Julia Starkova1, Julia Starkova2, Karolina Skvarova Kramarzova2, Katerina Rejlova2, Karel Fiser2, Ester Mejstriкова2, Harry Drabkin3, Jan Trka2

1 2nd Faculty of Medicine, Charles University, Prague, Czech Republic
2 CLIP, Dept.of Pediatric Hematology/Oncology, 2nd Faculty of Medicine, Charles University and Hospital Motol, Prague, Czech Republic
3 Medical University of South Carolina, Charleston, SC, USA

P 39

Use of 10-colour flow to detect MRD in ALL improves concordance with PCR-MRD results

Rosemary Sutton1, Mary Sartor2, Tamara Law1, Anuruddhika Dissanyake1, Nicola C Venn1, Mawar Karsa1, Toby Trahair1, Draga Barbaric2, Luciano Dalla Pozza1, Murray D Norris1, Kenneth Bradstock4

1 Children’s Cancer Institute Australia
2 Institute of Clinical Pathology and Medical Research, Westmead Hospital, Australia
3 Sydney Children’s Hospital
4 Westmead Hospital, Australia

P 40

Dual purpose RQ-PCR based tests for CRLF2 and IKZF1 gene deletions in ALL

Rosemary Sutton1, Walter Muskovic2, Nicola C Venn1, Jodie E Giles1, Tamara Law1, Anuruddhika Dissanyake1, Toby Trahair1, Glenn M Marshall2, Luciano Dalla Pozza3

1 Children’s Cancer Institute Australia
2 Sydney Children’s Hospital, Australia
3 Children’s Hospital at Westmead, Australia
P 41
Recovery of the normal B cell compartment in children treated for acute lymphoblastic leukemia
Prisca Theunissen1, Ester Mejstrikova2, Lucasz Sedek3, Tomasz Szczepanski3, Alita van der Sluijs4, Alberto Orfao5, Jacques van Dongen1, Vincent van der Velden1
1 Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
2 Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University (DPH/O), Prague, Czech Republic
3 Department of Pediatric Hematology and Oncology, Medical University of Silesia (SUM), Zabrze, Poland
4 Dutch Childhood Oncology Group, The Hague, The Netherlands
5 Cancer Research Center (IBMCC-CSIC), Department of Medicine and Cytometry Service, University of Salamanca (USAL) and Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain

P 42
Hyperactive Ras signalling in refractory ETP-ALL
Frederik van Delft1, Marcela Mansur2, Alison Morilla2, Claire Stephens2, Sue Colman2, Donat Alpar2, Mary Taj3, Victoria Weston4, Julie Irving5, Tony Ford2, Mel Greaves2
1 NICR, Newcastle University, UK
2 ICR, London, UK
3 Royal Marsden Hospital, London, UK
4 Birmingham University, UK
5 NICR, Newcastle upon Tyne, UK

P 43
Prognostic Value for the CXCR4/CXCL12 Axis in Pediatric Precursor B-cell Acute Lymphoblastic Leukemia
Lieke van den Berk1, Arian van der Veer2, Marieke Willemse2, Myrte Theeuwes2, Mirjam Luijendijk2, Wing Tong2, Inge van der Sluijs2, Rob Pieters2, Monique den Boer2
1 Department of Pediatric Oncology/Hematology, Erasmus MC – Sophia Children’s Hospital, Rotterdam, The Netherlands
2 Erasmus MC – Sophia Children’s Hospital, Rotterdam, The Netherlands

P 44
Loss of Tumor Suppressor BTG1 Promotes Cell Survival by Controlling Cellular Adaptation to Stress
Laurens van der Meer, Laurensia Yuniati, Esther Tijchon, Liesbeth van Emst, Manon Alkema, Caroline Rodenbach, Blanca Scheijen, Peter Hoogerbrugge, Frank van Leeuwen
Radboud University Medical Centre, Nijmegen, The Netherlands

P 45
IKZF1 deletions are correlated to an unfavorable outcome in BCR-ABL1-positive B-cell precursor acute lymphoblastic leukemia independent of imatinib exposure
Arian van der Veer1, Marketa Zaliova2, Federica Mottadelli3, Paola De Lorenzo4, Gertruuy te Kronnie5, Rob Pieters6, Andrea Biondi3, Maria Grazia Valsecchi5, Martin Stanulla7, Monique L. Den Boer1, Giovanni Cazzaniga3
1 Erasmus MC – Sophia Children’s Hospital, Rotterdam, The Netherlands
2 Department of Pediatrics, University Medical Center Schleswig – Holstein, Kiel, Germany
3 Centro Ricerca Tettamanti, Clinica Pediatrica, University of Milano – Bicocca, Monza, Italy
4 EsPhALL Trial data Center, Department of Health Sciences, University of Milano – Bicocca, Monza, Italy
5 Department of Women’s and Children’s Health, University of Padova, Padova, Italy
6 Dutch Childhood Oncology Center, The Netherlands
7 Pediatric Hematology/Oncology Hannover Medical School, Germany
TCF3-rearranged BCP-ALL is characterized by an activated pre-B-cell receptor pathway and may be treated with ibrutinib

Arian van der Veer1, Vincent H. J. van der Velden2, Marieke E. Willems1, Patricia G. Hoogeveen2, Emanuel F. Petricoin3, H. Berna Beverlo4, Gabriele Escherich5, Martin A. Horstmann5, Rob Pieters6, Monique L. Den Boer1

1 Erasmus MC – Sophia Children’s Hospital, Rotterdam, The Netherlands
2 Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
3 Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, USA
4 Department of Clinical Genetics, Erasmus MC, Rotterdam, the Netherlands
5 COALL study group, Research Institute Children’s Cancer Center and Clinic of Pediatric Oncology, University Medical Centre Eppendorf, Hamburg, Germany
6 Dutch Childhood Oncology Group, The Netherlands

Loss Of BTG1 Function Promotes Leukemic Transformation

Frank N. van Leeuwen1, Esther Tijchon1, Liesbeth van Emst1, Dorette van Ingen Schenau1, Laurens van der Meer1, Owen Williams2, Peter Hoogerbrugge1, Blanca Scheijen1

1 Radboud University Medical Centre, Nijmegen, The Netherlands
2 UCL Institute of Child Health, London, UK

Prognostic relevance of BTLA/CD200 deletion in pediatric pre-B cell acute lymphoblastic leukemia

Farzaneh Ghazavi1, Tim Lammens2, Stefan Suciu3, Marleen Bakkus4, Hélène Cavé5, Franki Speleman6, Yves Benoit2, Barbara De Moerloose2, Pieter Van Vlierberge6

1 Center for Medical Genetics, Ghent University Hospital, Belgium
2 Department of Pediatric Hematology – Oncology, Ghent University Hospital, Ghent, Belgium
3 EORTC Headquarters, Brussels, Belgium
4 VUB, Brussels, Belgium
5 Department of Genetics, Hôpital Robert Debré AP-HP, Paris, France
6 Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium

Independent development of lymphoid and myeloid malignancies from a common early progenitor

Esme Waanders1, Konnie M. Hebeda2, Patricia J.T.A. Groenen2, Annet Simons1, Frank N. Van Leeuwen3, Roland P. Kuiper1, D. Maroeska W.M. Te Loo3

1 Department of Human Genetics, Radboud university medical center and Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands
2 Department of Pathology, Radboud university medical center, Nijmegen, The Netherlands
3 Department of Pediatric Oncology, Radboud university medical center and Radboud Institute for Molecular Life Sciences, Nijmegen, the Netherlands

Impaired FPGS splicing as an emerging determinant of MTX resistance in ALL

Anna Wojtuszkiewicz1, Yehuda G. Assaraf2, Shachar Raz3, Michal Stark2, Kazunori Koide3, Edwin Sonneveld4, Godefridus J. Peters1, Gerrit Jansen1, Gerjjan L. Kaspers1, Jacqueline Cloos1

1 VU Medical Center, Amsterdam, The Netherlands
2 Technion – Israel Institute of Technology, Israel
3 University of Pittsburgh, USA
4 Dutch Childhood Oncology Group (DCOG), The Hague, The Netherlands
**P 51**

**ABCB11 and CHST11 are associated with risk of relapse in childhood acute lymphoblastic leukemia – Ma-Spore ALL 2003 study**

Marc Wong, Yi Lu, Shirley Kham, Allen Yeoh  
National University Health System, Singapore

---

**P 52**

**Modeling Resistance to Tyrosine Kinase Inhibitors in TEL/ABL+ Acute Lymphoblastic Leukemia**

Olga Zimmermannova, Jan Zuna, Katerina Machova Polakova, Libuse Lizova, Zuzana Zemanova, I-Ming Chen, Frederik Falkenburg, Richard Harvey, Cheryl Willman, Jan Trka, Marketa Zaliova  
1 CLIP – Childhood Leukaemia Investigation Prague, 2nd Faculty of Medicine, Charles University, Prague, Czech Republic  
2 Institute of Hematology and Blood Transfusion, Prague, Czech Republic  
3 Institute of Clinical Biochemistry and Laboratory Diagnostics, Center of Oncocytogenetics, 1st Faculty of Medicine, Charles University, Prague, Czech Republic  
4 Department of Pathology, University of New Mexico, Albuquerque, New Mexico, USA  
5 Department of Hematology, Leiden University Medical Center, Leiden, Netherlands

---

**P 53**

**Acute Neurologic Complication in children during Acute Lymphoblastic Leukemia Treatment**

Adalet Meral Gunes, Birol Baytan, Melike Sezgin Evim, Ozlem Ozdemir  
1 Uludag Univ. Fac. of Medicine Dpt. of Ped. Hematology and Oncology, Turkey  
2 Uludag Univ. Fac. of Medicine Dpt. of Ped. Neurology, Turkey

---

**P 54**

**A single center results of flowcytometric determination of minimal residual disease in pediatric B-ALL patients**

Davut Albayrak, Canan Albayrak  
Medical faculty of Ondokuz Mayis University, Samsun, Turkey

---

**P 55**

**ETV6/RUNX1-positive childhood acute lymphoblastic leukemia (ALL): do additional aberrations influence treatment response and outcome?**

Maria Ampatzidou, Stefanos Papadhimitriou, George Paterakis, Efthimia Rigatou, Loizos Petrikkos, Dimitris Pavlidis, Konstantinos Tsitsikas, George Vassilopoulos, Sophia Polychronopoulou  
1 Department of Pediatric Hematology and Oncology, “G.Gennimatas” General Hospital, Athens, Greece  
2 Hematology Laboratory, “G.Gennimatas” General Hospital, Athens, Greece  
3 Immunology Laboratory, “G.Gennimatas” General Hospital, Athens, Greece  
4 Department of Pediatric Hematology – Oncology, “Aghia Sophia” Childrens’ Hospital, Athens, Greece  
5 Department of Hematology, University Hospital of Larisa, Thessaly Medical School, Larisa, Greece

---

**P 56**

**MLL rearrangements in childhood acute lymphoblastic leukemia: clinical and genetic features of a distinct disease entity**

Maria Ampatzidou, Stefanos Papadhimitriou, Loizos Petrikkos, Dimitris Pavlidis, Konstantinos Tsitsikas, Efthimia Rigatou, George Paterakis, Sophia Polychronopoulou  
1 Department of Pediatric Hematology and Oncology, “G.Gennimatas” General Hospital, Athens, Greece  
2 Hematology Laboratory, “G.Gennimatas” General Hospital, Athens, Greece  
3 Department of Pediatric Hematology – Oncology, “Aghia Sophia” Childrens’ Hospital, Athens, Greece  
4 Immunology Laboratory, “G.Gennimatas” General Hospital, Athens, Greece
P 57
Characteristics and outcome of children with relapse of acute lymphoblastic leukemia. A single institution experience

Margarita Baka1, Dimitrios Doganis1, Apostolos Poursidis1, Despina Bouhoutsou1, Maria Varvoutsi1, Marina Servitzoglou1, Helen Dana1, Vassiliki Kitra2, Theodora Anastasiou1, Helen Kosmidis1
1 Oncology Department, Children's Hospital, Athens, Greece
2 Bone Marrow Transplantation Unit, Children's Hospital, Athens, Greece
3 Hematology lab, Children's Hospital, Athens, Greece

P 58
Second malignancies in children treated for acute lymphoblastic leukemia. A single institution experience

Margarita Baka1, Dimitrios Doganis1, Apostolos Poursidis1, Despina Bouhoutsou1, Maria Varvoutsi1, Marina Servitzoglou1, Helen Dana1, Maria Synodinou1, Theodora Anastasiou4, Helen Kosmidis1
1 Oncology Department, Children's Hospital, Athens, Greece
2 Radiotherapy department, Children's Hospital, Athens, Greece
3 Hematology lab, Children's Hospital, Athens, Greece

P 59
Clinical implication of BCR/ABL monitoring in addition to Ig/TCR gene rearrangement-based minimal residual disease in Philadelphia chromosome-positive childhood acute lymphoblastic leukaemia

Kirsten Bleckmann1, Julia Alten1, Anja Moericke1, André Schrauder1, Andrea Teigler-Schlegel2, Rolf Koehler3, Martin Schrappe1
1 Department of Paediatrics, University Medical Centre, Kiel, Germany
2 Department of Paediatric Hematology and Oncology, Oncogenetic Laboratory, Justus-Liebig-University, Giessen, Germany
3 Institute of Human Genetics, University of Heidelberg, Heidelberg, Germany

P 60
Does polymorphism 677 C>T of the gene of 5,10-methylenetetrahydrofolate reductase have influence on early toxicities of high dosage of methotrexate in children with acute lymphoblastic leukaemia?

Magdalena Cwiklinska1, Aleksandra Wieczorek1, Mirosław Bik-Multanowski2, Walentyna Balwierz1
1 University Children's Hospital of Cracow, Department of Oncology/Hematology, Jagiellonian University Medical College, Poland
2 Chair and Department of Pediatrics, University Children's Hospital of Cracow, Jagiellonian University Medical College, Poland

P 61
Underweight and weight loss negatively influences outcome in children with acute lymphoblastic leukemia

1 Erasmus MC – Sophia Childrens Hospital, Rotterdam, The Netherlands
2 Department of Pediatric Oncology/ Hematology, Erasmus MC – Sophia Children’s Hospital, Rotterdam, The Netherlands
3 Dutch Childhood Oncology Group, The Hague, The Netherlands
4 Department of Pediatric Endocrinology, Erasmus MC – Sophia Children’s Hospital, Rotterdam, The Netherlands
5 Department of Pediatric Haematology – Oncology, Nijmegen, Radboud University Medical Center Nijmegen, The Netherlands
6 Academic Medical Center, Amsterdam, The Netherlands
7 Willem-Alexander Children’s Hospital, Leiden University Medical Center, Leiden, The Netherlands
8 VU University Medical Center, Amsterdam, The Netherlands
9 Department of Pediatric Oncology/ Hematology, Erasmus MC – Sophia Children's Hospital, Rotterdam, the Netherlands
P 62
Genetic variation in methotrexate induced mucositis in pediatric acute lymphoblastic leukemia, a prospective study


1 Erasmus MC – Sophia Children’s Hospital, Rotterdam, The Netherlands
2 Department of Genetics, Physical Anthropology and Animal Physiology, University of the Basque Country (UPV/EHU), Leioa, Spain
3 Department of Pediatric Oncology/ Hematology, Erasmus MC – Sophia Children’s Hospital, Rotterdam, The Netherlands
4 Department of Oncology/ Hematology, University Medical Center Groningen – Beatrix Children’s Hospital, Groningen, The Netherlands
5 Department of Clinical Chemistry, Erasmus MC – University Medical Center, Rotterdam, The Netherlands

P 63
Fatal Neurological Side-Effects with Necrosis of Spinal Cord Following Nelarabine Treatment in a Child with Relapsed T- Cell Acute Lymphoblastic Leukemia

Gabriele Escherich, Bernd Hartz, Ulrike Löbel, Christian Hagel
University Hospital Hamburg Eppendorf, Germany

P 64
Association of genetic polymorphisms in RFC1, MTHFR, and SHMT1 on susceptibility and survival in early childhood acute lymphoblastic leukemia in Brazil

Maria S. Pombo de Oliveira1, Tállita Meciany Farias Vieira1, Luiz Claudio Santos Thuler2, Gisele Moledo Vasconcelos1, Bruno Alves de Aguiar Gonçalves1, Alessandra Faro1, Mariana Emerenciano1

1 Pediatric Hematology – Oncology Program, Instituto Nacional do Cancer, Rio de Janeiro, Brazil
2 Clinical Research, Research Center, Instituto Nacional de Câncer, Rio de Janeiro, Brazil

P 65
Early T Acute Lymphoblastic Leukemia in childhood: prevalence and clinical characteristics

Jorge Rossi1, Carolina Carrara2, Patricia Rubio2, Cristina Alonso2, Andrea Bernasconi2, Elisa Sajaroff2, Mariela Cocce2, Marta Gallego2, Silvia Eandi Eberle2, Maria Ibarrola2, Adrián Mansini2, Patricia Luna4, Maria Vides Herrera2, Cesy Pedrini2, Maria Felice2

1 Hospital de Pediatría J P Garrahan, Servicio de Inmunología y Reumatología, Buenos Aires, Argentina
2 Hospital de Pediatría J P Garrahan, Buenos Aires, Argentina
3 Laboratorio de Redes y Programas, Argentina
4 Hospital del Niño Jesús, Argentina
5 Hospital Eva Perón, Argentina
6 Hospital Juan Pablo II, Argentina

P 66
Chromosomal translocation t(13;14)(q14.q32) in a patient with B-acute lymphoblastic leukemia associated with poor prognosis: a case report

Maressa Ferreira Neto, Ibere Cauduro Soares, Maicon Fernando Zanon da Silva, Daniel Onofre Vidal, Aline Tansini, Cristovam Scapulatempo Neto, Bianca Faustini, Luiz Fernando Lopes
Barretos Cancer Hospital, Brazil

P 67
Immune reconstitution inflammatory syndrome treated with adjuvant steroid in a child with leukemia and possible hepatic candidiasis

Dildar Bahar Genc, Sema Vural, Nafiye Urganci, Tugce Kurtarener, Akcahan Baloglu
Sisli Etfal Education and Research Hospital, Istanbul, Turkey
Experience with clofarabine as consolidation treatment in children with diagnosis of refractory or relapsed acute lymphoblastic leukemia

Myriam Guitter1, Cristian Sanchez La Rosa2, Elizabeth Alfaro2, Jorge Rossi2, Elisa Sajaroff2, Marta Gallego3, Cristina Alonso2, Pedro Zubizarreta2, Maria Sara Felice2

1 Raffo, Buenos Aires, Argentina
2 Hospital Nacional de Pediatría Prof. Dr. Juan P Garrahan, Buenos Aires, Argentina

Subunite A of Coagulation Factor XIII as a New Biomarker In Childhood Acute Lymphoblastic Leukemia?

Katalin Gyurina1, László Csáthy2, Gábor Kiss3, Silvia Bresolin4, Geertruy te Kronnie4, Zsuzsa Hevessy2, István Szegedi1, Giuseppe Basso4, Csongor Kiss1, János Kappelmayer2

1 Institute of Pediatrics, Department of Hematology – Oncology, University of Debrecen, Hungary
2 Department of Laboratory Medicine, University of Debrecen, Hungary
3 NovaScienza Ltd, Hungary
4 Department of Women’s and Children’s Health, University of Padova, Italy

Peripheral blood lymphocyte recovery and overall survival in pediatric acute lymphoblastic leukemia (ALL)

Emmanuil Hatzipantelis, Zoe Dorothea Pana, Maria Vlachou, Theodotis Papageorgiou, Maria Hatzistilianou

Pediatric Hematology-Oncology Unit, 2nd Pediatric Department of Aristotle University of Thessaloniki, AHEPA General Hospital, Greece

Is intravenous immunoglobulin substitution associated with relapse of pediatric acute lymphoblastic leukemia by inducing regulatory T cells?

Katja Heitink-Polle, Janlouis Bezemer, Marrie Bruin

University Medical Center Utrecht, The Netherlands

Childhood Acute Lymphoblastic Leukemia: Experience with BFM 95 in a Tertiary Care Cancer Centre in India

Gauri Kapoor

Rajiv Gandhi Cancer Institute & Research Centre, Pediatric Hematology Oncology, India

Jumping translocations in bone marrow cells of children with hematologic malignancies

Libuse Lizcova1, Zuzana Zemanova1, Eva Malinova1, Marie Jarosova2, Milena Holzerova2, Petr Smisek3, Martina Sukova4, Ester Mejstrikova4, Jan Stary4, Kyra Michalova1

1 General University Hospital and First Faculty of Medicine, Charles University in Prague, Czech Republic
2 Department of Hemato – Oncology, University Hospital and Palacky University Olomouc, Czech Republic
3 Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University, Prague and University Hospital Motol, Prague, Czech Republic
4 CLIP – Childhood Leukaemia Investigation Prague, Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University, Prague and University Hospital Motol, Prague, Czech Republic
Augmenting clinical interpretability of thiopurine methyltransferase laboratory evaluation

Martina Mrkvicova1, Regina Demlova2, Jaroslav Sterba3, Jan Stary4, Martina Sukova4, Alena Mikuskova1, Alica Chocholova5, Beata Mlasosievicova6, Katerina Pilatova1, Lenka Zdrazilova Dubska1

1 Masaryk Memorial Cancer Institute, Brno, Czech Republic
2 Masaryk University School of Medicine, Brno, Czech Republic
3 University Hospital Brno, Brno, Czech Republic
4 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
5 Department of Paediatric Haematology and Oncology, Children’s University Hospital, Bratislava, Slovakia
6 Institute of Pathological Physiology, Comenius University School of Medicine, Bratislava, Slovakia

Multiparameter flow cytometry and routine microscopy for detecting peripheral blasts in pediatric acute lymphoblastic leukemia: a comparative study

Sergey Nikulshin, Zhanna Kovalova, Iveta Tolstikova, Marika Grutupa, Gunita Medne, Dagne Gravele

University Children’s Hospital, Riga, Latvia

Incidence of prognostically relevant chromosome abnormalities in pediatric acute lymphoblastic leukemia (ALL) in Russia: Results of the Russian study group Moscow-Berlin (MB)

Yulia Olsanskaya1, Anna Kazakova1, Elena Matveeva1, Natalia Timofeeva1, Svetlana Lagoiko1, Julia Rumiantseva1, Oleg Bydanov2, Ludmila Baidun2, Guenter Henze1, Alexander Karachunskii1, Alexander Rumyantsev1

1 Federal Scientific and Clinical Centre of Pediatric Hematology, Oncology and Immunology named after Dmitry Rogachev Ministry of Health of Russian Federation
2 Belarusian Research Centre for Pediatric Oncology, Haematology and Immunology
3 Russian Federal Children Hospital

Post-induction minimal residual disease monitoring by PCR in children with acute lymphoblastic leukemia: is it useful to predict relapse?

Maddalena Paganin1, Giulia Fabbri2, Valentino Conter3, Elena Barisone4, Katia Polato2, Giovanni Cazzaniga2, Franca Fagioli4, Maurizio Aricò5, Maria Grazia Valsecchi7, Giuseppe Basso2

1 Laboratorio di Oncoematologia, Dipartimento di Pediatria, Università di Padova, Italy
2 Laboratorio di Oncoematologia, Dipartimento di Salute della Donna e del Bambino, Università di Padova, Italy
3 Clinica Pediatria, Università Milano – Bicocca, Ospedale San Gerardo, Monza, Italy
4 S.C. Oncoematologia Pediatrica e Centro Trapianti, Ospedale Infantile Regina Margherita, Torino, Italy
5 Tettamanti Research Center, Pediatric Clinic, University of Milano Bicocca, Milano, Italy
6 Istituto Toscano Tumori (I.T.T.), Rete Regionale Oncoematologia Pediatrica, Firenze, Italy
7 Centro di Biostatistica per l’Epidemiologia Clinica, Università di Milano Bicocca, Monza, Italy

MLL rearrangements in childhood ALL of B-cell origin with no pro-B phenotype: association with cytoplasmic μ and light chain restriction

George Paterakis1, Anna Tapakou2, Stefanos Papadhimitriou3, Anastasia Athanasiadou4, Maria Ampatzidou5, Maria Kouri6, Dimitris Pavlidis1, E. Farmaki2, Vassilios Papadakis2, Efthicia Stiakaki7, Dimitris Kolioukas6, Sophia Polychnopoulou5

1 Immunology Laboratory “G. Gennimatas” Hospital, Athens, Greece
2 First Department of Pediatrics, Aristotle University, “Hippokratia” General Hospital Thessaloniki, Greece
3 Hematology Laboratory “G. Gennimatas” Hospital, Athens, Greece
4 Hematology Department “G. Papanikolaou” Hospital, Thessaloniki, Greece
5 Department of Pediatric Hematology – Oncology, “Aghia Sophia” Childrens Hospital, Athens, Greece
6 Department of Pediatric Oncology, Hippokration General Hospital, Thessaloniki, Greece
7 Department of Pediatric Hematology – Oncology University of Crete, Heraklion, Greece
P 79
Mature B acute lymphoblastic leukemia (mB-ALL) with MLL rearrangements
in childhood: report of three cases
Elisa Olga Sajaroff, Adrian Mansini, Patricia Rubio, Mariela Cocce, Andrea Bernasconi, Marta Gallego,
Cristina Alonso, Maria Felice, Jorge Rossi
Hospital de Pediatría J P Garrahan, Buenos Aires, Argentina

P 80
Prognostic value of minimal residual disease (MRD) on day 33 and 78 in patients
previously stratified by MRD on day 15
Elisa Olga Sajaroff¹, Patricia Rubio¹, Andrea Bernasconi¹, Paz Ibarrola², Myriam Guitter¹, Cesy Pedrini³,
Patricia Luna³, Maria Fernandez Barbieri³, Maria Vides Herrera³, Ezequiel Recondo³, Marta Gallego¹,
Cristina Alonso¹, Maria Felice¹, Jorge Rossi¹
¹ Hospital de Pediatría J P Garrahan, Buenos Aires, Argentina
² Laboratorio de Redes y Programas
³ Hospital de Pediatría Juan Pablo II, Argentina

P 81
Does dexamethasone induce more neuropsychological side effects than
prednisone in pediatric acute lymphoblastic leukemia? A systematic review
Lidewij Warris, Marry van den Heuvel, Marissa den Hoed, Rob Pieters, Erica van den Akker
Erasmus MC – Sophia Children’s Hospital, Rotterdam, The Netherlands

P 82
Outcome of children with Down syndrom and acute lymphoblastic leukaemia
in Poland
Joanna Zawitkowska¹, Teresa Odój², Julia Rudnicka², Katarzyna Drabko², Anna Kitszel³,
Maryna Krawczuk-Rybak³, Andrzej Kołtan⁴, Mariusz Wysocki⁴, Maciej Niedźwiecki⁵, Anna Balcerska⁵,
Kinga Kwiecinska⁶
¹ Department of Paediatric Hematology, Oncology and Transplantology UM, Krakow, Poland
² Department of Paediatric Haematology, Oncology and Transplantology, Lublin, Slovenia
³ Paediatric Haematology, Oncology, Białystok, Poland
⁴ Paediatric Haematology, Oncology, Bydgoszcz, Poland
⁵ Paediatric Haematology, Oncology, Gdansk, Poland
⁶ Paediatric Haematology, Oncology, Kraków, Poland

P 83
Impact of additional structural aberrations in bone marrow cells of children
with acute lymphoblastic leukemia (ALL) and high hyperdiploidy
Zuzana Zemanova¹, Libuse Lízcova¹, Linda Bartu¹, Eva Malinova¹, Petr Smisek¹, Iveta Janotova², Ester Mejeríkova²,
Jan Stára², Kyra Michalova¹
¹ General University Hospital and First Faculty of Medicine, Charles University in Prague, Czech Republic
² Department of Pediatric Hematology and Oncology, Charles University Prague, 2nd Faculty of Medicine
and University Hospital Motol, Czech Republic
P 84
L-asparaginase related toxicity, preliminary results from the ALLIC 2010 GATLA protocol

Virginia Schuttenberg1, Fynn Alcira2, Arrieta Elizabeth3, Borchichi Sandra4, Calvo Carina5, Caferri Horacio6, Daloi Karina7, Drozdzowski Constanza8, Hollman Carlos9, Matus Monica10, Majek Elena11, Murray Cecilia12, Negri Pedro13, Gomel Matilde14, Freigeiro Daniel7, Riccheri Cecilia13

1 Hospital de Ninos sor Maria Ludovica, Buenos Aires, Argentina,
2 HNLP, Argentina
3 HNSAN JUAN, Argentina
4 HMIS, Argentina
5 HNMDZ, Argentina
6 HIBB, Argentina
7 HINBA, Argentina
8 Clinica San Lucas, Argentina
9 HNCOR, Argentina
10 HNROS, Argentina
11 HN JU, Argentina
12 MMMDP, Argentina
13 HNP, Argentina
14 HNCH, Argentina

P 85
Outcome of treatment in childhood acute lymphoblastic leukaemia (ALL) with the t(4;11) MLL-AF4 traslocation. Report of GATLA institution

Virginia Schuttenberg1, Fynn Alcira2, Arbezu Guillermo3, Cedola Alejandra4, Hernandez Monica5, Matus Monica6, Tramunt Bibiana7, Freigeiro Daniel8, Riccheri Cecilia9

1 Hospital de Ninos sor Maria Ludovica, Buenos Aires, Argentina
2 HNLP, Argentina
3 HNMDZ, Argentina
4 Clinica San Lucas. Argentina
5 HIBB, Argentina
6 HINROS, Argentina
7 HIN JU, Argentina
8 HN JU, Argentina
9 HNP, Argentina

P 86
Should We Use a Desensitization Protocol In Acute Lymphoblastic Leukemia Patients With Silent Inactivation Of PEGasparaginase?

Wing Tong1, Rob Pieters1, Wim Tissing2, Inge van der Sluis1

1 Erasmus MC – Sophia Children’s Hospital, Rotterdam, The Netherlands
2 University Medical Center Groningen, The Netherlands

P 87
A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia

Wing Tong1, Rob Pieters1, Gertjan Kaspers2, Maroeksa te Loo3, Marc Bierings4, Cor van den Bos5, Wouter Kollen6, Claudia Lanvers-Kaminsky7, Mary Relling8, Wim Tissing9, Inge van der Sluis1

1 Erasmus MC – Sophia Children’s Hospital, Rotterdam, The Netherlands
2 UMC Amsterdam, The Netherlands
3 UMC Nijmegen, The Netherlands
4 UMC Utrecht, The Netherlands
5 AMC Amsterdam, The Netherlands
6 LUMC Leiden, The Netherlands
7 UMC Muenster, Germany
8 St Jude Children’s Research Hospital Memphis, USA
9 UMCG Groningen, The Netherlands
P 88
Safety of Asparaginase Erwinia chrysanthemi in a Large Compassionate-Use Trial: Subanalysis of Newly Diagnosed and Relapsed Patients
Paul V. Plourde1, Taheri Mercedes1, Tim Corn2
1 Jazz Pharmaceuticals, Inc.; Palo Alto, CA, USA
2 EUSA Pharma (an international division of Jazz Pharmaceuticals); Oxford, UK

P 89
Safety of Asparaginase Erwinia chrysanthemi in a Compassionate-Use Trial: a Subanalysis of the Adolescent/Young Adult Patient Population
Paul V. Plourde1, Taheri Mercedes1, Tim Corn2
1 Jazz Pharmaceuticals, Inc.; Palo Alto, CA, USA
2 EUSA Pharma (an international division of Jazz Pharmaceuticals); Oxford, UK

P 90
Quantitative detection of minimal residual disease in childhood Burkitt’s lymphoma/leukemia by RT-qPCR with patient-specific primers for MYC-IgH rearrangement
Alina Fedorova1, Victoria Lavrinenko2, Tatyana Savitskaya2, Olga Aleinikova2
1 Belarusian Center for Paediatric Oncology, Haematology and Immunology, Minsk, Belarus
2 Belarusian Research Center for Pediatric Oncology, Hematology and Immunology, Belarus

P 91
Minimal disseminated and minimal residual disease assessment in childhood lymphoblastic lymphoma by flow cytometry analysis
Alina Fedorova1, Lyudmila Movchan2, Artem Zhavrid2, Mihail Belevtsev2, Olga Aleinikova2
1 Belarusian Center for Paediatric Oncology, Haematology and Immunology, Minsk, Belarus
2 Belarusian Center for Pediatric oncology, hematology and immunology, Minsk, Belarus

P 92
B-cell mature leukemia / lymphoma: experience of a single institute in 20-year period
Marina Servitzoglou, Apostolos Pourtsidis, Despina Bouhoutsou, Mary Varvoutsi, Margarita Baka, Dimitrios Doganis, Helen Dana, Helen Kosmidis
Children’s Hospital, Athens, Greece

P 93
Neonatal Acute Myeloid Leukemia, the French Experience
Wadih Abou Chahla1, Yoann Huguenin2, Pascale Blouin3, Jacqueline Clavel1, Yves Perel5, Brigitte Nelken6, Guy Leverger7
1 Jeanne de Flandre hospital CHRU Lille, France
2 Department of Pediatric Hematology – Oncology, Pellegrin Hospital, CHU Bordeaux, France
3 Department of Pediatric Hematology, CHU de Tours, France,
4 Inserm U1018, Center for Research in Epidemiology and Population Health (CESEP) Equipe, France
5 Department of Pediatric Hematology – Oncology, Pellegrin Hospital, CHU Bordeaux, France
6 Pediatric Hematology Unit, Pôle Enfant, Jeanne de Flandre Hospital, CHU Lille, France
7 Department of Pediatric Hematology-Immunology-Oncology, Armand Trousseau Hospital, AP-HP, Paris, France

P 94
Incidence and clinical impact of FLT3, NPM1 and CEBPa mutations in childhood AML in Argentina
Cristina Noemi Alonso, Patricia Rubio, Adriana Medina, Silvia Eandi Eberle, Andrea Bernasconi, Mariela Coccé, Marta Gallego, Jorge Rossi, Pedro Zubizarreta, Maria Felic
Hospital de Pediatría J P Garrahan, Buenos Aires, Argentina
P 95
Frequency of molecular aberrations in a large cohort of childhood acute myeloid leukemia in Brazil

Maria S. Pombo de Oliveira¹, Francianne Gomes Andrade¹, Érika Menezes de Mendonça¹, Alejandro Mauricio Arancibia², Ana Maria Marinho da Silva³, Eny Guimarães Carvalho³, Isis M.Q. Magalhães⁴, Andrea Gadelha Nobrega⁴, Marcelo Santos-Silva⁴, Ilana Zalcberg Renault⁵, Terezinha J. Marques-Salles
¹ Pediatric Hematology – Oncology Program, Instituto Nacional do Cancer, Rio de Janeiro, Brazil
² Hospital Amaral Carvalho, Jau, São Paulo, Brazil
³ Martagão Gesteira Hospital da Criança, Salvador, Brazil
⁴ Children Hospital, Brasilia, Brazil
⁵ Napoleao Laureano Hospital, Joao Pessoa, PB, Brazil
⁶ Rosa Pedrossian Hospital – CETOHl, Campo Grande, MS, Brazil
⁷ Laboratory of Molecular Biology, Bone Marrow Transplant Center, INCA, Rio de Janeiro, RJ, Brazil
⁸ Oswaldo Cruz University Hospital – CEON, Recife, PE, Brazil

P 96
Central venous catheter complications during treatment for childhood acute myeloid leukemia

Margarita Baka, Marina Servitzoglou, Despina Bouhoutsou, Mary Varvoutsi, Apostolos Poursidis, Dimitrios Doganis, Helen Dana, Helen Kosmidis
Oncology Department, Children’s Hospital, Athens, Greece

P 97
Infectious complications during treatment for childhood acute myeloid leukemia

Margarita Baka, Marina Servitzoglou, Apostolos Poursidis, Despina Bouhoutsou, Mary Varvoutsi, Dimitrios Doganis, Helen Dana, Helen Kosmidis
Oncology Department, Children’s Hospital, Athens, Greece

P 98
Invasive fungal infections in children with acute myeloid leukemia

Margarita Baka, Marina Servitzoglou, Apostolos Poursidis, Despina Bouhoutsou, Mary Varvoutsi, Dimitrios Doganis, Helen Dana, Helen Kosmidis
Oncology Department, Children’s Hospital, Athens, Greece

P 99
Immunotherapy of Acute Leukemias with Chimeric Antigen Receptors (CARs)-engineered Cytokine Induced Killer (CIK) cells by Sleeping Beauty System

Chiara Francesca Magnani¹, Nice Turazzi¹, Fabrizio Benedicenti², Sarah Tettamanti¹, Greta Maria Paola Giordano Atlanese¹, Vincenzo Rossi¹, Eugenio Montini², Laurence JN Cooper³, Alessandro Aiuti², Andrea Biondi¹, Ettore Biagi¹
¹ Centro Ricerca Tettamanti, Clinica Pediatrica, Universita Milano Bicocca, Osp. San Gerardo/Fondazione MBBM, Italy
² San Raffaele Telethon Institute for Gene Therapy (HST-TIGET), Milan, Italy
³ University of Texas, MD Anderson Cancer Center, Houston, Texas, USA

P 100
Prophylactic administration of teicoplanin to prevent infection with streptococcus viridans in pediatric patients with acute myeloid leukemia

Heidrun Boztug, Nora Mühllegger, Andishe Attarbaschi, Georg Mann, Wolfgang Holter, Michael Dworzak
St. Anna Childrens Hospital, Medical University Vienna, Austria
P 101
Features and outcome of an intriguing cluster of non Down syndrome acute megalakaryoblastic leukemia
José Luis Fuster1, Juan F Pascual-Gámez2, Ana M Galera-Miñarro3, Mar Bermúdez-Cortés3, Andrés Sánchez-Salinas3, Jose A Campillo3, Alfredo Minguela3, Carmen Garcia-Insauti2, Joaquin Gómez-Espuch3, Miguel Blanquer2, Jose M Moraleda2
1 Unidad de Oncohematología Pediátrica Hospital Clínico Universitario Virgen de la Arrixaca Ctra. Madrid, Spain
2 Hematopoietic transplantation and Cell Therapy Unit/Hospital Universitario Virgen de la Arrixaca, Spain

P 102
Acute promyelocytic leukemia (APL) in children. GATLA experience
Alcira Fynn1, Moran Lorena2, Freigeiro Daniel3, Aversa Luis4, Riccheri Cecilia5, Elena Graciela5, Deana Alejandra4, Negri Pedro6, Cedola Alejandra7, Bietti Julietta8, Zirone Sandra9, Reichel Paola10
1 Raffo, Buenos Aires, Argentina
2 HNBA, Argentina
3 HNBA, Argentina
4 HNP, Argentina
5 HNE, Argentina
6 HNSF, Argentina
7 Clinica San Lucas, Argentina
8 HNROS, Argentina
9 HNROS, Argentina
10 Hosp. Eva Peron, Argentina

P 103
Case Report: Various MLL-breakpoints in a patient having AML with translocation t(9;11) show different response to medication
Maike Hinrichs1, Christine von Neuhoff1, Julia Alten2, Nils von Neuhoff1, Dirk Reinhardt1
1 Medizinische Hochschule Hannover, Germany,
2 Universitätsklinikum Schleswig-Holstein-Campus Kiel, Germany

P 104
Somatic thrombopoietin gene mutations are rare in childhood acute myeloid leukemia and myeloproliferative disease
Maite Houwing1, Rogier Kersseboom2, Saskia Gooskens1, Andría de Vries1, Dirk Reinhardt3, Jan Stary4, André Baruchel5, Valerie de Haas4, Rob Pieters1, Michel Zwaan1, Marry van den Heuvel-Eibrink1
1 Department of Pediatric Oncology/Hematology, Erasmus MC – Sophia Children’s Hospital, Rotterdam, The Netherlands
2 Department of Clinical Genetics, Erasmus MC, Rotterdam, The Netherlands
3 Acute Myeloid Leukemia Berlin – Frankfurt – Munster Study Group, Department of Pediatric Oncology/Hematology, Medical School, Hannover, Germany
4 Department of Pediatric Oncology/Hematology, Charles University and University Hospital Motol, Prague, Czech Republic
5 Department of Hematology, Hôpital Robert Debré, Paris, France
6 Dutch Childhood Oncology Group, The Hague, The Netherlands

P 105
Genetic engineering in patient-derived AML cells by lentiviral transduction enables highly sensitive in vivo imaging in mice
Irmela Jeremias1, Binje Vick1, Michela Carlet1, Cornelia Finkenzeller1, Selim Corbacioglu2, Martin Ebinger3, Wolfgang Hiddemann4, Maya André5, Karsten Spiekermann5
1 Helmholtz Center Munich, Germany
2 Universitätskinderklinik Regensburg, Germany
3 Universitätskinderklinik Tübingen, Germany
4 Ludwig Maximilians University Munich, Germany
5 University Children’s hospital Basel (UKBB), Switzerland
P 106

Prevalence and clinical significance of genetic abnormalities in acute myeloid leukemia (AML) in children: Polish population-based study

Teofilá Ksiazek1, Walentyna Balwierz1, Małgorzata Czogala1, Michał Matysiak2, Elżbieta Adamkiewicz-Drożynska3, Jerzy Kowalczyk4, Mariusz Wysocki5, Jacek Wachowiak6, Alicja Chybicka7, Maryna Krawczuk-Rybak8, Wojciech Młynarski9, Tomasz Szczepanski10, Grazyna Sobol11, Joanna Podhorecka12, Maria Wieczorek13, Wanda Badowska14

1 Pediatric, Oncology and Hematology Department, PA Institute of Pediatrics, Jagiellonian University Medical College, Krakow, Poland
2 Department of Pediatrics, Hematology and Oncology, Medical University, Warsaw, Poland
3 Department of Pediatrics, Hematology, Oncology and Endocrinology, Medical University of Gdansk, Gdansk, Poland
4 Department of Hematology and Oncology, Medical University, Lublin, Poland
5 Department of Pediatrics, Hematology and Oncology, Institute of Pediatrics, Medical Academy, Bydgoszcz, Poland
6 Department of Pediatric Oncology, Hematology and Transplantology, University of Medical Sciences, Poznan, Poland
7 Department of Pediatric Transplantology, Oncology and Hematology, Medical Academy of Wroclaw, Wroclaw, Poland
8 Department of Pediatric, Hematology and Oncology, Medical University, Białystok, Poland
9 Department of Pediatrics, Hematology, Oncology and Endocrinology, Medical University, Lodz, Poland
10 Department of Pediatric, Hematology and Oncology, Silesian Medical University, Katowice, Poland
11 Oncology and Hematology Unit of Pediatric Department, Silesian Medical University, Katowice, Poland
12 Oncology and Hematology Unit of Pediatric Hospital, Kielce, Poland
13 Pediatrics and Oncology Center, Chorzow, Poland
14 Oncology and Hematology Unit of Pediatric Hospital, Olsztyn, Poland

P 107

Prognostic significance of FLT3 internal tandem duplication in children with high risk acute myeloid leukemia: Polish experience

Teofilá Ksiazek1, Walentyna Balwierz1, Katarzyna Pawinska-Wasikowska1, Barbara Fic-Sikorska2, Lucyna Maciejka-Kapucinska3, Beata Wojcik4, Sylwia Koltan5, Kinga Potocka6, Katarzyna Muszynska-Roslan7, Małgorzta Stolarska8, Renata Tomaszewska9, Agnieszka Mizia-Malarz10, Grazyna Karolczyk11, Irena Karpinska-Derda12, Wanda Badowska13

1 Pediatric, Oncology and Hematology Department, PA Institute of Pediatrics, Jagiellonian University Medical College, Krakow, Poland
2 Department of Pediatrics, Hematology and Oncology, Medical University, Warsaw, Poland
3 Department of Pediatrics, Hematology, Oncology and Endocrinology, Medical University of Gdansk, Gdansk, Poland
4 Department of Hematology and Oncology, Medical University, Lublin, Poland
5 Department of Pediatrics, Hematology and Oncology, Institute of Pediatrics, Medical Academy, Bydgoszcz, Poland
6 Department of Pediatric Transplantology, Oncology and Hematology, Medical Academy of Wroclaw, Wroclaw, Poland
7 Department of Pediatric, Hematology and Oncology, Medical University, Białystok, Poland
8 Department of Pediatrics, Hematology, Oncology and Endocrinology, Medical University, Lodz, Poland
9 Department of Pediatric, Hematology and Oncology, Silesian Medical University, Katowice, Poland
10 Oncology and Hematology Unit of Pediatric Department, Silesian Medical University, Katowice, Poland
11 Oncology and Hematology Unit of Pediatric Hospital, Kielce, Poland
12 Pediatrics and Oncology Center, Chorzow, Poland
13 Oncology and Hematology Unit of Pediatric Hospital, Olsztyn, Poland

P 108

Cytogenetic and molecular genetic abnormalities evaluation in Pediatric Acute Myeloblastic Leukemia

Javad Sabery Nejad1, Azim Mehrvar2, Maryam Tashvighi2, Amir Abbas Hedayati Asl2, Mohammad Faranoush2, Asghar Ramyar1, Leili Kuchakzadeh1, Farzad Kompany1, Mohammad Saeid Rahiminejad1

1 Children Center Hospital, Iran
2 MAHAK’s Pediatric Cancer Treatment and Research Center, Iran
P 109
Childhood Acute Myeloid Leukemia at Mahak’s Pediatric Cancer Treatment and Research Center in Iran
Maryam Tashvighi, Mohammad Faranoush, Amir Abbas Hedayati-Asl, Ehsan Abadi, Naljes Mehrvar, Vahid Fallah-Azad, Azim Mehrvar
Mahak’s Pediatric Cancer Treatment Research Center, Iran

P 110
Outcome of children with relapsed acute myeloid leukemia following initial therapy by Japanese AML99 protocol
Hideki Nakayama1, Akio Tawa2, Kazuko Kudo3, Hiromasa Yabe4, Akira Shimada5, Keizo Horibe6, Takako Miyamura7, Hiroshi Moritake8, Daisuke Tomizawa9, Takashi Taga10, Souichi Adachi11
1 Fukuoka – Higashi Medical Center, Japan
2 Osaka Medical Center, Japan
3 Shizuoka Children’s Hospital, Japan
4 Tokai University School of Medicine, Japan
5 Okayama University School of Medicine, Japan
6 Nagoya Medical Center, Japan
7 Osaka University School of Medicine, Japan
8 Miyazaki University School of Medicine, Japan
9 Tokyo Medical and Dental University, Japan
10 Shiga University Medical Science, Japan
11 Kyoto University, Japan

P 111
Anthracycline-reduced therapy for Down syndrome AML is well-tolerated and effective – UK & ROI experience 2008–2013
Oliver Tunstall1, Aengus O’Marcaigh2
1 Bristol Royal Hospital for Children, UK
2 The Hospital for Sick Children, Dublin, Ireland

P 112
Spanish SHOP AML-2001 protocol. Long term evaluation
Amparo Verdeguer1, Susana Rives2, Fernández NAVarro José MAria3, Susana Riesco4, Isabel Badell5
1 Pediatric Oncology and Pediatric Hematopoietic Cell Transplantation Unit Clinical and Translational Investigation Group La Fe Hospital Universitario Infantil La Fe, Valencia, Spain
2 H Sant Joan de Deu, Spain
3 H La Fe, Spain
4 H La Paz, Spain
5 H Sant Pau, Spain

P 113
Characterization of subpopulations and single cell analysis in pediatric acute myeloid leukemia
Christiane Walter, Lisa Kellerstrass, Katarina Reinhardt, Nils von Neuhoff, Dirk Reinhardt
Hannover Medical School, Germany
P 114
Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndromes in Children: An Argentinean Experience
Adriana Berretta¹, Ana Lisa Basquiera¹, María Victoria Suen¹, Silvia Pizzi², Agustín González Correas², Pablo Longo³, María Virginia Prates⁴, Sandra Formisano⁵, Gregorio Jaimovich⁴, Raquel Staciuk², Juan José García¹
¹ Hospital Privado Centro Médico de Córdoba, Argentina
² Hospital de Pediatria SAMIC Prof. Dr. Juan Pedro Garrahan, Buenos Aires, Argentina
³ Hospital Austral, Argentina
⁴ Hospital Italiano de La Plata, Argentina
⁵ Hospital de Niños Sor Ludovica de la Plata, Argentina
⁶ Fundación Favaloro, Argentina

P 115
Use of azacitidine in children with advanced myelodysplastic syndromes (MDS) and juvenile myelomonocytic leukemia (JMML) – Experience of the Brazilian Cooperative Group of Pediatric MDS
Adriana Seber¹, Roseane V. Gouveia², Neysimelia C. Villela³, Maria Lucia Martino Lee⁴, Elvira D. R. P. Velloso⁵, Silvia C. Toledo⁶, Elizabeth Xisto Souto⁷, Poliana C. Molinari⁷, Luiz Fernando Lopes⁷
¹ Hospital Samaritano, Brazil
² Instituto Oncologia Pediatrica IOP/GRAACC/UNIFESP, Brazil
³ Pediatric Cancer Hospital Barretos, Brazil
⁴ Faculdade Medicina USP – São Paulo, Brazil
⁵ Hospital Brigadério e Laboratorio Lavoisier, Brazil
⁶ GENDACC-JUNDIAI, Brazil
⁷ Pediatric Cancer Hospital-Barretos-Chairman MDS Ped Brazilian Group, Brazil

P 116
Therapy with low-dose azacitidine for pediatric MDS and JMML: a retrospective analysis of the EWOG-MDS study group
Annamaria Cseh, Charlotte Niemeyer, Ayami Yoshimi, Brigitte Strahm, Christian Flotho
Division of Pediatric Hematology/Oncology, Department of Pediatrics and Adolescent Medicine, University of Freiburg, Germany

P 117
Xenologous Engraftment Of Juvenile Myelomonocytic Leukemia In Rag2null/γcnull Mice
Christian Flotho, Felix Krombholz, Miriam Erlacher, Daniela Bertele, Charlotte Niemeyer
Pediatric Hematology/Oncology, University of Freiburg, Germany

P 118
Noonan syndrome peripheral blood cells show enhanced spontaneous colonies growth in vitro and hyperactive RAS intracellular signalling pathways
Giuseppe Gaipa¹, Cristina Bugarin¹, Paola Cianci², Angelo Selicorni², Andrea Biondi¹
¹ M. Tettamanti Research Center, Pediatric Clinic, University of Milan Bicocca, Monza, Italy
² Pediatrics Clinical Genetics, MBBM AO San Gerardo Monza Foundation, University of Milano Bicocca, Italy

P 119
Central review of morphology in childhood aplastic anemia and myelodysplastic syndrome in Japan-summary of 1,000 cases
Asahito Hama¹, Atsushi Manabe², Daisuke Hasegawa², Kazue Nozawa³,Hideki Muramatsu¹, Yoshiyuki Takahashi¹, Akira Ohara⁴, Masafumi Ito⁵, Seiji Kojima¹
¹ Department of Pediatrics, Nagoya University Graduate School of Medicine, Japan
² Department of Pediatrics, Nagoya University Graduate School of Medicine, Japan
³ Department of Transfusion Medicine, St. Luke’s International Hospital, Japan
⁴ Department of Transfusion Medicine, Toho University School of Medicine, Japan
⁵ Department of Pathology, Red Cross Nagoya 1st Hospital, Japan
Treatment of Pediatric CML in Tyrosine Kinase Inhibitors Era – Slovak Experiences

Andrea Hraskova1, Judita Puskacova1, Alexandra Kolenova1, Julia Horakova1, Sabina Sufliafska2, Eva Bubanska3, Emilia Kaiserova1

1 Dept. of Pediatric Hematology and Oncology, Children’s University Hospital Bratislava, Slovakia
2 Dept. of Pediatric Hematology and Oncology, Transplantation Unit, Children’s University Hospital Bratislava, Slovakia
3 Dept. of Pediatric Hematology and Oncology, Slovak Medical University, Banská Bystrica, Slovakia

A patient of juvenile myelomonocytic leukemia with an NRAS mutation who developed acute lymphoblastic leukemia

Kazuko Kudo1, Akina Matsuoka1, Hideki Muramatsu2, Taemi Ogura1, Toshihiro Tomii1, Hironobu Kitazawa3, Rieko Ito1, Yasuo Horikoshi1, Seiji Kojima2

1 Shizuoka Children’s Hospital, Japan
2 Nagoya University Graduate School of Medicine, Japan
3 Shizuoka Children’s Hospital

Molecular cytogenetic studies unmasked chromosomal abnormalities in 4 cases of Fanconi anemia

Maria S. Pombo de Oliveira1, Terezinha de Jesus Marques-Salles1, Maria Luiza Rosa Borges1, Ademir de Jesus AmaralP, Marcela Maria Pereira de Lemos Pinto2, Thomas Liehr3, Hasmik Mkrtchyan4, Maria Teresa Marquim Nogueira Cornéllo1, Bethânia de Araujo Silva Amaral5, Eliane Maria Soares-Ventura6

1 Pediatric Hematology – Oncology Program, Instituto Nacional do Cancer, Rio de Janeiro, Brazil
2 Nuclear Energy Departament of – UFPE, Recife, Brazil
3 Jena University, Institute of Human Genetics, Jena, Germany
4 Laboratory of Cytogenetics Medicalcenter, Genetechnology, Moscow, Russia
5 Genetic Department, Federal of Pernambuco University, Recife, Brazil
6 Pediatric Oncohematology Center, Hospital Oswaldo Cruz, Pernambuco University, Recife, Brazil

Clinical significance and cytogenetic analysis of chromosome 7 aberrations in childhood leukemia: experiency of CEONHPE/UPE/Brazil

Maria S. Pombo de Oliveira1, Eliane Maria Soares-Ventura2, Maria Luiza Rosa Borges2, Marina Araújo Fonzar Hernandes2, Elizangela Ferreira da Silva2, Thomas Liehr3, Hasmik Mkrtchyan4, Maria Teresa Marquim Nogueira Cornéllo1, Terezinha de Jesus Marques-Salles2

1 Pediatric Hematology – Oncology Program, Instituto Nacional do Cancer, Rio de Janeiro, Brazil
2 Pediatric Oncohematology Center, of Oswaldo Cruz Hospital – Pernambuco University, Recife, Brazil
3 Institute of Human Genetics – Jena University, Jena, Germany
4 Laboratory of Cytogenetics of Medical center Genetechnology, Moscow, Russia

Chronic myeloid leukemia in child

Samia Menif Marrakchi
Institut Pasteur de Tunis, Laboratoire Hematologie, Tunisia
Simple fl ow cytometric and laboratory parameters help to discriminate between refractory cytopenia of childhood and aplastic anemia

Michaela Novakova1, Martina Sukova1, Vit Campi2, Gitte Kerndrup3, Elena Vodickova4, Ondrej Zapletal5, Dagmar Pospisilova6, Tomas Votava7, Katerina Lejhancova8, Oksana Fabri9, Peter Svec10, Market Zaliano1, Zuzana Zemanova11, Jan Stary1, Ondrej Hrusak1, Ester Meistrikova1

1 CLIP – Department of Paediatric Haematology and Oncology, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic
2 Department of Pathology and Molecular Medicine, Charles University, 2nd Faculty of Medicine and University Hospital Motol, Prague, Czech Republic
3 Department of Clinical Genetics, Vejle Hospital, Vejle, Denmark
4 Department of Clinical hematology, University Hospital Motol, Prague, Czech Republic
5 Department of Paediatric Haematology, Children’s University Hospital, Brno, Czech Republic
6 Department of Pediatrics, Palacky University and University Hospital Olomouc, Olomouc, Czech Republic
7 Department of Pediatrics, University Hospital Plzen, Plzen, Czech Republic
8 Department of Pediatrics, University Hospital Hradec Kralove and Charles University in Prague, Hradec Kralove, Czech Republic
9 Department of Laboratory Medicine, University Children's Hospital, Bratislava, Slovakia
10 Department of Paediatric Haematology and Oncology, University Children's Hospital, Bratislava, Slovakia
11 Center of Oncocytogenetics, Institute of Clinical Biochemistry and Laboratory Diagnostics, General University Hospital and 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic

Mind the gap: translation of genetic research into clinical care in the context of RUNX1 associated leukaemia predisposition

Tim Ripperger1, Alina Ferster2, Tim Lammens3, Barbara De Moerloose3, Laurence Rozen4, Nadira Azzi2, Charlotte M. Niemeyer5, Brigitte Schlegelberger6, Doris Steinemann6

1 Institute of Cell and Molecular Pathology, Hannover Medical School, Germany
2 Hematology – Oncology, Queen Fabiola Children’s University, Brussels, Belgium
3 Department of Pediatric Hematology-Oncology, Ghent University Hospital, Ghent, Belgium
4 Laboratory of hematology and haemostasis, Brugmann University Hospital, Brussels, Belgium
5 Division of Pediatric Hematology-Oncology, Department of Pediatric and Adolescent Medicine, University of Freiburg, Freiburg, Germany
6 Institute of Cell and Molecular Pathology, Hannover Medical School, Hannover, Germany

MDS/AML complicated with Behçet's Disease in 4 Pediatric Cases

Akira Shimada1, Kiichiro Kanamitsu2, Ritsuo Nishiuchi3, Tomonari Shigemura4, Yozo Nakazawa4, Kenichi Koike4, Yuichi Shinkoda2, Yoshifumi Kawano5, Hiroo Ueno6, Atuschi Manabe6

1 Okayama University Hospital, Japan
2 Department of Pediatrics, Okayama University Hospital, Japan
3 Department of Pediatrics, Kochi Health Science Center
4 Department of Pediatrics, Shinshyu University, Japan
5 Department of Pediatrics, Kagoshima University, Japan
6 Department of Pediatrics, St. Luke International Hospital, Japan

Chronic Myeloid Leukaemia in Pediatrics: Not just an adult malignancy in a juvenile host

Meinolf Suttorp1, Josephine T. Tauer1, Manuela Krumbholz2, Anna Ulmer1, Nils von Neuhoff3, Ingmar Glauche4, Brigitte Schlegelberger3, Christian Thiede5, Markus Metzler2

1 Dpt. of Pediatrics, Children's Hospital; Technical University Dresden, Germany
2 Dpt. of Pediatrics; Univ. Hospital, Erlangen, Germany
3 Inst. of Cellular – and Molecular Pathology; Medical School, Hannover, Germany
4 Inst. of Medical Informatics & Biometry; Medical Faculty, TU Dresden, Germany
5 Dpt. of Internal Medicine I; Univ. Hospital, TU Dresden, Germany
P 129
How much is enough: 4 stem cell transplantations, 3 donors, and one child with myelodysplastic syndrome (RAEB)
Marek Ussowicz1, Jakub Musiał1, Monika Mielcarek1, Dominika Kulej1, Ewa Gorczyńska1, Katarzyna Pawelec2, Krzysztof Kałwak1
1 Dept of Pediatric Hematology and Oncology, BMT Unit CIC 817, Wroclaw Medical University, Poland
2 Department of Pediatric Hematology and Oncology, Warsaw Medical University, Poland

P 130
Neutrophil Function Following Pediatric Hematopoietic Stem Cell Transplantation
Sivan Berger-Achituv1, Baruch Wolach2, Ronit Gavrieli2, Ayelet Shmueli Lavi1, Ronit Elhasid1
1 Tel-Aviv Sourasky Medical Center, Israel
2 Meir Medical Center, Kfar Saba, Israel

P 131
Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention?
Giovanni Cazzaniga1, Adriana Balduzzi2, Simona Songia3, Daniela Silvestri4, Lucia Di Maio2, Sonia Bonanomi2, Athilio Rovelli2, Valentino Contet2, Andrea Biondi2, Maria Grazia Valsecchi4, Giovanni Cazzaniga1
1 Centro Ricerca Tettamanti, Monza, Italy
2 Clinica Pediatrica, Università Milano Bicocca, Osp. San Gerardo/Fondazione MBBM, Monza, Italy
3 Centro Ricerca Tettamanti, Clinica Pediatrica, Università Milano Bicocca, Osp. San Gerardo/Fondazione MBBM, Monza, Italy
4 Centro Operativo di Ricerca Statistica, Univ. Milano – Bicocca, Monza, Italy

P 132
Peripheral stem cell transplantation from HLA haploidentical family donors with reduced toxicity conditioning regimen against refractory or very high risk childhood leukemia
Keisuke Kato1, Ai Yoshimi1, Tomohi Nakao1, Ryoko Suzuki2, Hiroko Fukushima2, Chie Kobayashi3, Takashi Fukushima2, Kazutoshi Koike1, Masahiro Tsuchida1
1 Division of Pediatric Hematology and Oncology, Ibaraki Children’s Hospital, Japan
2 Institute of Clinical Medicine, University of Tsukuba, Japan
3 Department of Pediatrics, Institute of Clinical Medicine, University of Tsukuba, Japan

P 133
Effect of KIR Ligand Mismatched SCT for Infantile ALL with MLL gene Rearrangement: A Report From the Japanese Pediatric Leukemia/ Lymphoma Study Group (JPLSG)
Takako Miyamura1, Masahiro Hirayama2, Kanji Sugita3, Tomoyuki Watanabe4, Katsuyoshi Koh5, Eiichi Ishii6, Koji Kato7, Akiko Moriya Saito8, Keizo Horibe9, Daisuke Tomizawa10
1 Department of Pediatrics, Osaka University, School of Medicine, Japan
2 Department of Pediatrics, Mie University, School of Medicine, Japan
3 Department of Pediatrics, Yamanashi University, School of Medicine, Japan
4 Department of Health and Nutrition, Aichi gakuin University, Japan
5 Department of Pediatrics, Saitama Children’s Medical Center, Japan
6 Department of Pediatrics, Ehime University, School of Medicine, Japan
7 Department of Hematology and Oncology, Japanese Red Cross Nagoya First Hospital, Japan
8 Clinical Research Center, National Hospital Organization Nagoya Medical Center, Japan
9 Clinical Research Center, National Hospital Organization Nagoya Medical Center, Japan
10 Department of Pediatrics, Tokyo Medical and Dental University, Japan
**P 134**

An experience of allogeneic haematopoietic stem cell transplantation in children in Republic of Kazakhstan

Kulyan Omarova, Aigul Tulebayeva, Saule Nukusheva

Kazakh Research Centre for Pediatrics and Children’s Surgery, Kazakhstan

**P 135**

Adoptive transfer of CMV specific T-cells as a treatment option for patients with poor functional CD8+ T-cell response to CMV

Ondřej Pelák¹, Ladislav Król¹, Šárka Rahmatová², Denisa Zlacká³, Petra Keslová¹, Petr Sedláček¹, Ondřej Hrušák¹, Tomáš Kalina¹

¹ Department of Paediatric Hematology and Oncology, 2nd Medical School, Charles University Prague, Czech Republic
² Department of Cell Therapy, Institute of Hematology and Blood Transfusion, Prague, Czech Republic

**P 136**

Intensification of chemotherapy in paediatric acute lymphoblastic leukaemia patients with high minimal residual disease before hematopoietic stem cell transplantation: does it make sense?

Lucie Sramkova, Kateřina Mužíková, Eva Froňková, Petr Sedláček, Jan Starý, Jan Trka

Dpt. of pediatric hematology and oncology, University Hospital Motol, Prague, Czech Republic

**P 137**

Non-T-depleted haploidentical hematopoietic stem cell transplantation in children with high risk acute myeloid leukemia

Natalia Subbotina, Igor Dolgopolov, Alexander Popa, Vasily Boyarshinov, Roman Pimenov, Georgy Mentkevich

Russian Cancer Research Center, Moscow, Russia

**P 138**

An experience of auto-HSCT in children in Republic of Kazakhstan

Aigul Tulebayeva, Kulyan Omarova, Saule Nukusheva

Kazakh Research Centre for Pediatrics and Children’s Surgery, Kazakhstan

**P 139**

The long time late effects of chemotherapy and cranial radiotherapy in childhood leukaemia

Gonul Aydogan, Sevgi Eltan, Arzu Akcay, Teoman Akcay, Deniz Tugcu, Zafer Salcioglu, Ferhan Akici, Hulya Sen, Muge Göke, Gonca Keskindemirci, Nuray Ayaz

Istanbul Kanuni Sultan Suleyman Education and Research Hospital, Turkey

**P 140**

Secondary malignancies in patients after treatment of acute lymphoblastic leukaemia in the Slovak republic

Emília Kaiserová¹, Anna Folloinova¹, Alexandra Kolenova¹, Zuzana Subova¹, Eva Bubanska¹, Irina Oravkinova², Ludmila Demitrovicova³, Eva Mikuskova³, Jozef Suvada¹, Judita Puskacova¹

² Dept. of Pediat. Hematol. Oncol., Kosice, Slovakia
³ National Cancer Institute, Bratislava, Slovakia
P 141
The prevalence of abnormal ovarian reserve in young female cancer survivors
Maryna Krawczuk-Rybak1, Elzbieta Leszczynska2, Marta Poznanska2, Beata Zelazowska-Rutkowska2, Jolanta Wysocka2
1 Medical University of Bialystok, Poland
2 Department of Pediatric Oncology and Hematology, Medical University of Bialystok, Poland
3 Department of Pediatric Laboratory Diagnostics, Medical University of Bialystok, Poland

P 142
Insulin resistance, adipokines and body fat in childhood cancer survivors
Eryk Latoch1, Katarzyna Muszynska-Roslan1, Agata Panas1, Anna Panasiuk1, Beata Rutkowska-Zelazowska2, Ewa Jaroszuk2, Maryna Krawczuk-Rybak1
1 Department of Pediatric Oncology and Hematology, Medical University of Bialystok, Poland
2 Department of Pediatric Laboratory Diagnostics, Medical University of Bialystok, Poland
3 Scientific Society of the Department of Pediatric Oncology and Hematology Medical University of Bialystok, Poland

P 143
Auxological parameters in children during and after ALL treatment according to ALL IC 2002 protocol
Katarzyna Muszynska-Roslan1, Marcin Jakub Kaminski2, Eryk Latoch1, Magdalena Kaminska2, Wioleta Skibniewska2, Ewa Jaroszuk2, Anna Panasiuk1, Maryna Krawczuk-Rybak1
1 Department of Pediatric Oncology and Hematology Medical University of Bialystok, Poland
2 Scientific Society of the Department of Pediatric Oncology and Hematology Medical University of Bialystok, Poland

P 144
Nationwide Evaluation of a Long-term Follow-up Diary for Childhood Cancer Survivors
Shuichi Ozono1, Yasushi Ishida2, Kentaro Aritaki3, Keiko Asami4, Miho Maeda5, Etsuko Yamaguchi6, Keizo Horibe7, Shunichi Kato8, Junichiro Fujimoto9, Tatsuo Kuroda10
1 Kurume University, Japan
2 Children’s Medical Center, Ehime Prefectural Central Hospital, Japan
3 Aritaki Children’s Clinic, Japan
4 Department of Pediatrics, Niigata Cancer Center Hospital, Japan
5 Department of Pediatrics, Niippon Medical School, Japan
6 Department of Pediatrics, Osaka city university, Japan
7 Clinical Research Center, National Hospital Organization Nagoya Medical Center, Japan
8 Department of Pediatrics, Tokai University, Japan
9 Clinical Research Center, National Research Institute for Child Health and Development, Japan
10 Department of Pediatric Surgery, Keio University School of Medicine, Japan

P 145
Characteristics and outcome of paediatric non-Hodgkin lymphoma patients with ovarian infiltration at presentation
Wendy van Dorp1, Catherine Owusuana2, Joop Laven3, Auke Beishuizen2, Marry van den Heuvel-Eibrink2
1 Erasmus MC – University Medical Center (Paediatric Oncology & Obstetrics and Gynaecology), Rotterdam, The Netherlands
2 Erasmus MC, Paediatric Oncology/ Haematology, Rotterdam, The Netherlands
3 Erasmus MC, Obstetrics and Gynaecology (reproductive medicine), Rotterdam, The Netherlands
Morphologic evaluation of cerebrospinal fluid in childhood acute leukemia patients can be difficult in case of low blast counts and may lead to overestimation of CNS-involvement

Alita J. van der Sluijs-Geling1, Vincent H.J. van der Velden2, Valérie de Haas1, Edwin Sonneveld1, Rob Pieters3, C. Michel Zwaan3
1 Dutch Childhood Oncology Group (DCOG), The Hague, The Netherlands
2 Department of Immunology, Erasmus Medical Centre, Rotterdam, The Netherlands
3 Pediatric Oncology/Hematology, Erasmus MC – Sophia Children’s Hospital, Rotterdam, The Netherlands

Cuplike Acute Myeloid Leukemia in children: association of a distinct cytomorphologic feature with presence of NPM1 and FLT3/ITD mutations

Valérie De Haas, Birgit E.M. van der Linden-Schrever, Hanne M. van Wijngaarden, Colette J.C. Dieltjes, Alita J. van der Sluijs-Gelling, Edwin Sonneveld
Dutch Childhood Oncology Group (DCOG), The Hague, The Netherlands

Successful Reconstructive Surgery following Pseudomonas Aeruginosa Orbital Cellulitis in a child with Acute Myelogenous Leukemia

Roula Farah1, Ghassan Asfahani1, Paul Audi2, Claude Alif1
1 Saint George Hospital University Medical Center, Lebanon
2 Trad Hospital, Lebanon

Juvenile myelomonocytic leukemia (JMML) with germline CBL mutation

Roula Farah1, Jessy Horkos1, Hussein Farhat2, Wassim Serhal2, Marco Zecca3, Miguel Abboud4
1 St George Hospital University Medical Center, Lebanon
2 University Medical Center Rizk Hospital, Lebanon
3 IRCSS polclinico San Matteo, Italy
4 American University of Beirut, Lebanon

Bone marrow necrosis in the relapse of childhood leukemia

Serap Karaman, Sema Anak, Zeynep Karakas, Aysegul Unuvar, Ahsen Celik, Ezgi Uysalol, Omer Devecioglu, Leyla Agaoglu
Istanbul University Istanbul Medical Faculty, Department of Pediatric Hematology-Oncology, Turkey

Tumor lysis syndrome in Non-Hodgkin lymphoma patients in the non-rasburicase era

Sema Vural1, Serap Karaman2, Gul Ozcelik1, Nurver Akinci1, Dildar Bahar Genc1
1 Sisli Etfal Education and Research Hospital, Turkey
2 Istanbul University Medical Faculty, Turkey
PTEN aberrations and mTOR amplifications are not correlated with poor prognosis in children with T-lineage Acute Lymphoblastic Leukemia (T-ALL)

Luca Lo Nigro¹, Paola Bonaccorso¹, Daniela Silvestri², Maria Grazia Silvestri², Elena Barisone³, Franco Locatelli⁴, Rosanna Parasole⁵, Maria Caterina Putti⁶, Valentino Conter⁷, Andrea Biondi⁷, Giuseppe Gaipa⁸, Giovanni Cazzaniga⁹

¹ Azienda Policlinico – OVE, Center of Pediatric Hematology Oncology, Catania, Italy
² University of Milan, Milano, Italy
³ Ospedale Regina Margherita, Torino, Italy
⁴ Ospedale Bambin Gesù, Roma, Italy
⁵ Ospedale Pausillipon, Napoli, Italy
⁶ Policlinico, Padova, Italy
⁷ Ospedale Nuovo San Gerardo Monza, Italy
⁸ Ospedale Nuovo San Gerardo, Monza, Italy

Successful treatment of a T-lineage Acute Lymphoblastic Leukemia very late isolated relapse, bearing a CALM-AF10 fusion transcript

Luca Lo Nigro¹, Emanuela Cannata², Piera Samperi¹, Carla Cimino², Silvia Marino², Elena Mirabile¹, Salvatore D’Amico¹, Giovanna Russo¹

¹ Azienda Policlinico – OVE, Center of Pediatric Hematology Oncology, Catania, Italy
² University of Catania, Italy

Safe and effective administration of Bortezomib in association with Rituximab in a child with relapsed/resistant B-cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)

Luca Lo Nigro¹, Emanuela Cannata², Piera Samperi¹, Carla Cimino², Silvia Marino², Silvana Munda¹, Milena La Spina¹, Vito Miraglia¹, Amelia Poli¹, Francesco Bellia¹, Andrea Di Cataldo², Giovanna Russo²

¹ Azienda Policlinico – OVE, Center of Pediatric Hematology Oncology, Catania, Italy
² University of Catania, Italy

CD2 positive B cell precursor acute lymphoblastic leukemia is characterized by demethylation in CEBPA promoter, frequent switch to monocytic lineage and MRD slow response

Ester Mejstrikova, Lucie Slamova, Julia Starkova, Karel Fiser, Eva Fronkova, Leona Rezkova-Reznickova, Marketa Zaliova, Kamila Polgarova, Jan Stary, Jan Trka, Ondrej Hrusak

CLIP-Department of Pediatric Hematology and Oncology Prague, 2nd Faculty of Medicine, Hospital Motol, Czech Republic

Flow cytometric findings in bone marrow and peripheral blood in patients with GATA-2 mutation

Ester Mejstrikova¹, Ales Janda², Michaela Novakova¹, Martina Sukova¹, Eva Fronkova¹, Marketa Zaliova¹, Jan Stary¹, Marcin Wlodarski², Ondrej Hrusak¹

¹ CLIP – Department of Pediatric Hematology and Oncology Prague, 2nd Faculty of Medicine, Hospital Motol, Czech Republic
² University of Freiburg, Department of Pediatrics, CCI, Division of Rheumatology, Germany
³ University of Freiburg PI, Bone Marrow Failure Group, Division of Pediatric Hematology and Oncology, Germany
P 157
Additional aberrations to the ETV6/RUNX1 gene fusion in Brazilian children with acute lymphoblastic leukemia: experience in a single institution
Marina Araújo Fonzar Hernandes1, Eliane Maria Soares-Ventura2, Maria Teresa Marquim Nogueira Cornéllo1, Maira Mafra2, Bethânia de Araújo Silva Amaral2, Emanuela Bezerra Gueiros2, Thomas Leihr5, Maria S. Pombo de Oliveira3, Terezinha de Jesus Marques Salles3, Maria Tereza Cartaxo Muniz1
1 Institute of Biology Sciences – Pernambuco University, Recife/Brazil
2 Pediatric Oncohematology Center, of Oswaldo Cruz Hospital – Pernambuco University, Recife/Brazil
3 Genetic Department – Federal University of Pernambuco, Recife/Brazil
4 Institute of Medical Sciences – Pernambuco University, Recife/Brazil
5 Institute of Human Genetics – Jena University, Jena/Germany
6 Pediatric Hematology – Oncology Program, Instituto Nacional do Cancer, Rio de Janeiro, Brazil

P 158
Clinical and cytogenetic profile of children with acute myeloid leukemia experience in a single institution in the north-eastern of Brazil
Eliane Maria Soares-Ventura1, Camila Buarque Cavalcanti2, Ulisses Montarroyos2, Bethânia de Araújo Silva Amaral3, Edinalva Pereira Leite4, Maria Luiza Macedo Silva5, Thomas Leihr6, Maria S. Pombo de Oliveira7, Terezinha de Jesus Marques Salles3, Maria Teresa Marquim Nogueira Cornéllo2
1 Oncohematology Center, Hospital Oswaldo Cruz, Pernambuco University, Recife, Brazil
2 Ciencies Biologic Institute, Pernambuco University
3 Genetic Department, Federal of Pernambuco University, Recife, Brazil
4 Pediatric Oncohematology Center, Hospital Oswaldo Cruz, Pernambuco University, Recife, Brazil
5 Cytogenetic Department of the National Center for Bone Marrow Transplant (CEMO-INCA), National Cancer Institute, Rio de Janeiro, Brazil
6 Jena University, Institute of Human Genetics, Jena, Germany
7 Pediatric Hematology – Oncology Program, Instituto Nacional do Cancer, Rio de Janeiro, Brazil

P 159
Successful treatment with electron beam therapy in a child with isolated cutaneous AML
Deniz Yilmaz Karapinar1, Nihal Karadaş2, Serra Arun Kamer2, Yavuz Anacak2, Yeşim Aydinok2, Can Balkan2, Buket Erer Delcastello2, Kaan Kavaklı2
1 Ege University Medical School, Children’s Hospital, Turkey
2 Radiation Oncology, Bornova – Izmir, Turkey

P 160
Severe rare mycotic infections in children receiving empirical antifungal caspofungin treatment for febrile neutropenia
Deniz Yilmaz Karapinar1, Nihal Karadaş2, Pınar Yazıcı1, Muhterem Duyu1, Yeşim Aydinok1, Dilek Metin1, Süleyha Hilmimolu Polat2, Bülent Karapinar1, Can Balkan1, Kaan Kavaklı1
1 Ege University Faculty of Medicine, Children’s Hospital, Bornova, Izmir, Turkey
2 Ege University Faculty of Medicine, Clinical Microbiology, Turkey
EXHIBITION & SPONSORS

EXHIBITION FLOORPLAN

3rd floor
Congress floor

LIST OF EXHIBITORS
1 Octapharma
2 Grifols
3 Pharmore + Nova Labs
4 Baxter
5 EUSA Pharma
6 MSD
7 CSL Behring
8 MRC-Holland
9 Amgen

EXHIBITION OPENING HOURS
Monday April 28 08:30–18:00

SPONSORS COMPANY PROFILES
We would like to sincerely thank following companies for generous contribution to the 9th Childhood Leukemia Symposium.

GOLD CATEGORY

EUSA Pharma

About EUSA Pharma
EUSA Pharma focuses on in-licensing, developing and marketing late-stage oncology, oncology supportive care and critical care products. EUSA Pharma currently has seven products on the International market: Erwinase® and Kidrolase® for treatment of acute lymphoblastic leukaemia; Caphosol® for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy; Xenazine®, for treatment for movement disorders; Collatamp®, a collagen and antibiotic surgical implant; Custodiol®, a tissue preservative solution used in organ transplantation; and Fomepizole®, an antidote for ethylene glycol poisoning. EUSA Pharma is now an International Division of Jazz Pharmaceuticals.

About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc is an international specialty biopharmaceutical company dedicated to helping patients with unmet medical needs. We identify, develop and commercialize innovative products in focused therapeutic areas, with a strong commercial focus and expertise in narcolepsy, oncology, pain and psychiatry. For more information on Jazz Pharmaceuticals please visit JazzPharmaceuticals.com.
EXHIBITION & SPONSORS

SPONSORS COMPANY PROFILES

SILVER CATEGORY

**Amgen**
Amgen discovers, develops, manufactures, and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science’s promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people’s lives. For more information, visit [www.amgen.com](http://www.amgen.com) and follow us on [www.twitter.com/amgen](http://www.twitter.com/amgen).

**Astellas**
In a global context, Astellas Pharma represents one of the 25 largest pharmaceutical companies. Major domain of company activities are oncology, urology, transplantation medicine, dermatology, therapy of infectious diseases and pain treatment. Astellas Pharma employs up to 17,000 people worldwide and its branches can be found in 33 countries on five continents. Astellas ambition is to become a global leader in selected therapeutical disciplines. In accordance with this aim, very intense research programmes are going on in a series of research institutes in Asia, America and Europe. The survey is focused primarily on distinguishing disciplines of the company but also on new fields with a special need for therapeutical innovation – such as diabetology, metabolic diseases or central nervous system disorders.

**Sigma-Tau**
Dedicated to providing new therapies and new hope to people with rare diseases
Sigma-Tau Rare Disease is a research-based pharmaceutical company focused on the discovery of molecules and therapies to help improve the lives of people who suffer from rare diseases.
The company’s primary focus is on haematology/oncology – an area in which Sigma-Tau has a strong track record of bringing novel therapeutics to market. Recognising the continuing vital need for better treatments, it invests in the research and development and commercialisation of novel therapeutics; the aim is to speed doctors’ and patients’ access to crucial therapies and thus make a positive impact on patients’ lives.
Sigma-Tau Rare Disease employs 220 staff across Europe and North America, with an R&D team based in the USA and in Switzerland.

For more information: Call +44 (0)1753 751 010
Email: raredisease@sigma-tau.co.uk
Web: [sigma-tau.co.uk](http://sigma-tau.co.uk)
SPONSORS COMPANY PROFILES

BRONZE CATEGORY

MSD

Today’s MSD is a global healthcare leader. From developing new therapies that treat and prevent disease to helping people in need, we’re committed to improving health and well-being around the world. MSD is known as Merck inside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.msd.com.

UNDER AUSPICES

University Hospital in Motol

The mission of University Hospital in Motol is treatment of illnesses based on actual pieces of medical knowledge and to provide complex and specialized high quality care for all stages of human life. The mission is summed up in our motto: fnmotol.cz: “serving generations”. Our main plan for future is to make the hospital “flag ship” of Czech health service in general and specialized care. In order to achieve our goals it is extremely important to have an effective plan for operating the hospital, including a plan for increasing the quality of health care.

Our hospital:
• Provides basic, specialized and super specialized health care and services in medical fields in form of outpatient and in-patient care for children, adults and elderly patients
• The biggest health care facility in CZ
• Is built in two single blocks that are connected together as well as few separate pavilions – has 2,410 beds
• More than 860,000 people per year are treated as outpatients
• More than 70,000 people are treated as in patients
• Has more than 5,000 employees
SOCIAL EVENTS

SUNDAY, APRIL 27

CONCERT @ CAROLINUM
Carolinum, 20:00
Included in both I-BFM & CLS registration fees

A classical concert will be held at Great Aula of Charles University founded in 1348 by Charles IV, King of Bohemia and King of the Romans, as the first Studium generale north of the Alps and east of Paris. Charles University is thus one of the oldest European universities.

**Concert teaser:** Maurice Ravel, Bohuslav Martinu, Alexej Fried· Leonard Bernstein, Astor Piazzola performed by Ensemble Martinu.

**No transportation** provided (please use your free public transportation tickets which is part of your registration).

**Address:**
Carolinum – Charles University, Ovocny trh 3, Praha 1

**How to reach Carolinum from the venue:**

By metro: From “Vysocanska” station (line B) take metro direction Zlicin. Exit at the station “Namesti Republiky” direction “Namesti Republiky” or station “Mustek” direction “Na Prikope” and then follow the directions from the map.
MONDAY, APRIL 28

CLS WELCOME DINNER

St. Agnes Convent, 20:00
Admission fee: EUR 70,-

The welcome reception of the 9th Biennial CLS will take place at St. Agnes Convent, a first class historical site of Prague, place where history meets present.

Enjoy meeting your colleagues and other delegates in a relaxed atmosphere with a delicious Czech cuisine. You will have a chance to visit the Czech National Gallery collections (Medieval Art in Bohemia) located on the 1st floor of the St. Agnes Convent.

Admission fee: EUR 70,-

Transportation (to/from) is arranged. Part of the evening is a short guided tour (30 min) through Old Town of Prague, please wear comfortable shoes.

Meeting point: Busses will be waiting in front of the venue main entrance 19:15.
TRANSPORTATION

FREE PUBLIC TRANSPORT TICKET

Please note that no shuttle service will be provided from the hotels to the venue during the meeting/symposium.

Free Public transport ticket will be provided instead (included in the registration package).
Ticket is valid as of Saturday, April 26 – Tuesday, April 29, 2014.

AIRPORT SHUTTLE SERVICE

Organised shuttle will be provided from the Venue to Airport – you need to pre-book this service – limited places.

Back to Airport on Tuesday (April 29, 2014) at 14:00 – price is EUR 15,-.
Pre-book at the Registration desk by Monday.

PRAGUE PUBLIC TRANSPORT

The public transport in Prague is very easy and efficient. The journey from Vaclav Havel Airport to the venue takes approx. 40 minutes. To the city center 25 minutes.

METRO

The Prague Metro network consists of 3 lines designated by letters and differentiated in colour: A - green colour, B - yellow colour, C - red colour, with transfers possible at Museum station (lines A and C), Mustek station (lines A and B), Florenc station (lines B and C). Metro operates daily from 5:00 to 24:00.

TRAMS

Daytime operation is from 4:30 to 24:00. Night time operation is from 00:30 to 4:30 and is provided by tram numbers 51 to 58 with traffic intervals 30 minutes. The central transfer station for night time lines is Lazarska stop. Tram schedules are located at individual stops.

BUSES

The daytime and night time operation of buses is similar to tram operation. Night time service is provided by bus numbers 501 to 514. Bus schedules are located at individual stops.
HOW TO GET FROM THE VENUE TO THE AIRPORT

Take metro Line B (yellow) in direction "Zlicín" to the final station "Zlicín". Change to the bus nr. 100 that will take directly to the Vaclav Havel Airport Prague.

TAXI

There are various taxi companies operating in Prague.

When taking a taxi, be sure that the taxi is equipped with a permanently installed yellow roof lamp with the TAXI sign in black letters. The registration number, company name and the price list including the basic rate – rate per kilometre and one-minute waiting rate must be displayed on both front doors of the taxi. These prices must correspond with the prices set on the meter in the taxi.

Customers are recommended to order a taxi with 24-hrs dispatching offices where the information on fares is available in advance.

AAA Taxi provides an excellent taxi service within Prague (phone no. 14014).

---

**Public transport tickets and passes**

<table>
<thead>
<tr>
<th>TICKET / PASS TYPE</th>
<th>Adult</th>
<th>Child</th>
<th>Junior</th>
<th>Student</th>
<th>Senior</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Basic 90 min.</strong></td>
<td>32 CZK</td>
<td>16 CZK</td>
<td>32 CZK</td>
<td>32 CZK</td>
<td>16 CZK</td>
</tr>
<tr>
<td>Short-term 30 min.</td>
<td>24 CZK</td>
<td>12 CZK</td>
<td>24 CZK</td>
<td>24 CZK</td>
<td>12 CZK</td>
</tr>
<tr>
<td>1 day 24 hrs.</td>
<td>110 CZK</td>
<td>55 CZK</td>
<td>110 CZK</td>
<td>110 CZK</td>
<td>55 CZK</td>
</tr>
<tr>
<td>3 days 72 hrs.</td>
<td>310 CZK</td>
<td>•</td>
<td>310 CZK</td>
<td>310 CZK</td>
<td>•</td>
</tr>
</tbody>
</table>

• No reduced fares for this tariff group.
A

Accommodation
Should you need any help with your accommodation, please contact our staff at the registration desk.

B

Badges
Each participant will receive a name badge at the registration. Badges must be worn at all times to enable session attendance and social activities.

C

Certificate of attendance
The certificate of attendance will be provided on the last day of the Symposium (Tuesday, April 29, 2014).

Coffee breaks
Coffee/tea will be served during the morning and afternoon breaks at the exhibition area on the Congress Floor (3rd).

Currency
Currency is Czech Crown.
Exchange rate 1 EUR = 27,3 CZK (in April 2014).

Exchange offices are located throughout the city centre (Airport, Main Railway station, Metro stations) as well as in the banks and post offices. It is advisable to exchange money in banks rather than in the street exchange offices.


ATM machine is available at the venue complex (Shopping Gallery Fenix) as well as 3 banks (Komercni banka, CSOB, Unicredit bank. Banks are located on Upper level of Shopping Gallery Fenix that is connected with venue – Clarion CHP.

Banks opening hours
Friday 09:00–16:00
Weekend closed
Monday, Tuesday 09:00–18:00

D

Dates
CLS – April 28–29, 2014

E

Emergency numbers
Valid anywhere in the Czech Republic and you can dial free of charge from any public call box.

General Emergency number 112
Fire Brigade 150
Ambulance 155
Police 158

Electrical appliances
If you are planning to bring electrical equipment (e.g. battery chargers, laptop power supply, etc.), please check whether you need an adapter. Electrical power is rated 220–230V at 50Hz. Most common power outlets are designed for a two-pin Euro plug.

G

Guided tours
Meeting is always 15 minutes before the scheduled departure at the Registration desk. Please take your vouchers received prior to the event via email.

I

Information
The registration desk staff will be happy to help you on any questions you may have with regards to the Meeting or any other matter. Assistance / Information – Technical staff will be in each of the meeting rooms ready to help you.
Insurance
The Organisers do not accept liability for personal injury or loss or damage to private property of participants and accompanying persons either during or while travelling to the Meeting.

Internet
CCHP (venue) has provided our participants with FREE WiFi connection in all public areas.

Network name (SSID): Congress
Login: IBFMCLS2014
Password: IBFMCLS2014

Each login is valid for 24 hours. You will be asked to login again when the session expires.

Internet corner (with a printer) sponsored by Novartis will also be available in the exhibition area.

Language
The official language of the meeting is English.

Lost and found
A lost and found service is available at the registration desk.

Lunches
Lunches will be served upon presentation of a valid voucher.
Monday, April 28 at the exhibition area (lunch box)

BiTE® Antibodies
Designed to Bridge T Cells to Cancer Cells

Amgen (Europe) GmbH
Dammstrasse 23
CH-6300 Zug
Switzerland
www.amgen.com

© 2014 Amgen Inc. All rights reserved.
BMB-IHQ-AMG-386-2013 July NP. 07.2013

Oncology
M

Mobile phones
Participants are kindly requested to keep their mobile phones in the off position (silent mode) while session is being held.

P

Photo
No photo allowed during scientific sessions.

Programme changes
The organisers cannot assume liability for any changes in the programme due to external or unforeseen circumstances.

R

Registration
Onsite registration is not possible.
All documents including meeting bag can be picked up during following opening hours:
- Sunday April 27 08:00–18:30
- Monday April 28 08:00–18:00 (CLS)
- Tuesday April 29 08:00–13:00 (CLS)

S

Shopping
Gallery Fenix
Multifunctional space: shops, restaurants, banks…
www.galeriefenix.eu

Smoking
Smoking is forbidden in the venue.

Social programme
Please see page 46 for further details on the Social programme.

T

Transportation
Free public transport passes are kindly provided by city of Prague, they are valid from Saturday, April 26 through Tuesday April 29, 2014.

No shuttle transfers organised from hotels to venue.
For detailed info about transportation please visit the Transportation part – page 48.

Tipping
In restaurants guests usually tip the waiter with about 5–10%.

U

Useful links
I-BFM SG www.bfm-international.org
Meeting organizer C-IN www.c-in.eu
Prague www.praguewelcome.cz
Czech Republic www.czechtourism.com

V

Venue
Clarion Congress Hotel Prague
Freyova 33
Prague 9 - Vysocany
Tel.: +420 211 131 139
Web: www.cchp.cz

W

Weather
Prague is a city with a “mild continental climate”. The average temperature in April varies between 8°C and 15°C.
Daily updated weather information for Prague can be found here:
www.yr.no/place/Czech_Republic/Prague/Prague
LEPŠÍ UČINNOST
VEND® prokázal lepší odporův na léčbu a lépe přežijí ve svornění a omotávání B u invazivní aspergilózy.

ŠIROKÝ SPEKTRUM ÚČINKU
- Aspergillus spp.
- Candida spp. (včetně C. krusei)
- Scedosporium spp.
- Fusarium spp.

LEPŠÍ SNÁŠELOVOST A MĚNĚ NEŽÁDOUCÍ ÚČINKŮ NEŽ AFOTERICIN B

Zdrojové informace o přípravce: VEND® 100 mg, potahované tabletty - VEND® 200 mg, prášek pro injekci různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různých různ chí
The organizers of the 9th CLS 2014 in Prague wish to thank the following companies for their generous contributions:

**GOLD SPONSOR**

**SILVER SPONSORS**

**BRONZE SPONSOR**

**OTHER SPONSORS**

**Under auspices of**

Česká hematologická společnost ČLS JEP

FN MOTOL